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ABSTRACT 
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD), 
where prolonged exposure to hyperglycemia induces damage to proximal tubule cells of 
the kidney. Since progression to ESRD correlates to pathological changes in the tubular 
segments of the kidney, the effects of hyperglycemia in the PT portion of the nephron 
may be particularly relevant to the progression of DN. Development of this disease also 
is likely to occur in the context of exposure to other renal toxins, and the heavy metal 
cadmium (Cd2+) may be the most relevant due to the accumulation of this metal in the 
major cell type involved in glucose reabsorption: proximal tubule cells. Preliminary 
microarray analysis has shown human proximal tubule (HPT) cells exposed acutely and 
chronically to Cd2+ have an increased expression of an aldose reductase (AR) isoform, 
AKR1B10. This isoform along with AKR1B1 and sorbitol dehydrogenase (SORD) are 
involved in glucose metabolism under hyperglycemic conditions via the polyol pathway. 
The goal of this study was to verify and extend these observations in culture of HPT 
cells. For this purpose, HPT cells were exposed to one of the three following treatments; 
5.5 (control), 7.5, 11, or 16 mM glucose concentrations for 8 days; 9, 27, 45 μM Cd2+ for 
24 hours (acute), or 4.5, 9, 27 μM Cd2+ for 13 days (chronic). Real-time PCR was used to 
measure the expression level of these enzymes. Exposures to either hyperglycemia or 
Cd2+ stimulated a significant induction of AKR1B10 in HPT cells; however, exposure to 
xiii 
 
these renal toxins had no effect on AKR1B1 or SORD expression. We also observed 
glucose-induced loss of epithelial morphology that correlated to an induction of N- 
Cadherin (CDH2), a mesenchymal marker. These results are suggestive of potential 
synergistic effects of Cd2+ and hyperglycemia in the toxic responses of the proximal 
tubules during the development of DN. 
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CHAPTER I.I 
INTRODUCTION 
Impact 
Diabetes mellitus is one of the most prevailing pathologies in today’s society 
affecting more than 25.8 million people in the United States, making it the 7th leading 
cause of death (American Diabetes Association; Yu & Bonventre, 2018). Diabetes 
mellitus is characterized by chronic hyperglycemia and microvascular complications in 
the renal glomerulus (nephropathy), retina (retinopathy), peripheral nerve (neuropathy) 
(M Brownlee, 2001; Sheetz & King, 2002). Diabetes mellitus is a complicated disease 
that affects not only the kidneys but is also known to induce vascular problems in other 
regions of the body that can lead to limb amputations, cardiovascular disease, blindness, 
etc. ( American Diabetes Association ; Das & Srivastava, 1985). A high interest in 
mechanistic research into diabetes mellitus is sparked by the awareness of the health 
problems associated with this disease. 
Diabetic nephropathy (DN) is one of the most serious complications of diabetes 
mellitus (Edwards & Prozialeck, 2009; Suarez, Thomas, Barisoni, & Fornoni, 2013; 
Tervaert et al., 2010). Diabetic nephropathy is a microvascular disease where prolonged 
exposure to hyperglycemia induces damage to various cells of the kidney, ultimately 
developing into chronic kidney disease (CKD) (Kanwar, Sun, Xie, Liu, & Chen, 2011). 
Some of the renal morphological changes that occur in diabetic nephropathy are 
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basement membrane thickness, accumulation of extracellular matrix proteins, glomerular 
and renal hypertrophy, fibrosis, a decline in glomerular filtration rate, etc. (Kanwar et al., 
2011; Macisaac, Ekinci, & Jerums, 2014; Schrijvers, De Vriese, & Flyvbjerg, 2004). 
Once there is a detection of proteinuria, end-stage renal disease quickly follows. The 
mechanism(s) of diabetic nephropathy are highly complicated and poorly understood, 
making the disease more difficult to treat.  
Some known risk factors that contribute to diabetic nephropathy have been 
identified such as hyperglycemia and diet. Exposure to prolonged hyperglycemic 
conditions can have detrimental effects on the kidney by activating metabolic and 
signaling pathways where downstream targets result in morphological and functional 
changes. These detrimental effects can lead to acute kidney injury and if not treated it can 
progress into a more damaging and irreversible state. Although there are several known 
contributing risk factors for diabetic nephropathy, there still may be unidentified 
environmental factors that can make an individual more susceptible to hyperglycemic 
damage or cause the disease to progress into a more advanced, damaging state.  
With regards to environmental factors, there is a growing body of evidence to 
support Cd2+ exposure contributes to the development of chronic kidney disease but also 
increases the severity of hyperglycemic damage on the kidneys (Edwards & Prozialeck, 
2009; Gobe & Crane, 2010; Klaassen, Liu, & Diwan, 2009; Prozialeck & Edwards, 2012; 
Thévenod, 2003). Therefore to properly understand diabetic nephropathy and the 
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mechanisms behind the disease progression, it’s important to understand how these 
toxicants induce irreversible damage in diabetic nephropathy. Also, understanding the 
pathological mechanisms behind diabetic nephropathy can provide health professionals 
the means for an early detection and prevention of the disease, as well as its progression.  
Acute and Chronic Kidney Disease 
Development of kidney diseases can occur rapidly (acute) or over long periods of 
time (chronic).  Acute kidney injury  is a reversible, sudden, rapid loss of the kidneys’ 
excretory functions that is clinically seen by the accumulation of urea (BUN) or 
creatinine in the blood, decreased urine output, or a combination of both which normally 
dissipates within a week of initial diagnosis (Basile, Anderson, & Sutton, 2012; Bellomo, 
Kellum, & Ronco, 2012; Levey, Levin, & Kellum, 2013). Acute kidney injury is caused 
by several independent events such as dehydration, surgery, use of medicines, or 
overnight hospital stays (Chawla, Eggers, Star, & Kimmel, 2014). Although acute kidney 
injury is an independent disease, however if there is not a full recovery from the acute 
kidney injury it will make the patient more susceptible to disease progression to chronic 
kidney disease.   
Chronic kidney disease is defined as an irreversible, gradual loss of the kidneys’ 
excretory functions with the presence of kidney damage (i.e. albuminuria) which is 
evident for three months or longer (Levey & Coresh, 2012). Renal damage that is 
associated with chronic kidney disease is caused by the loss of viable nephrons. 
Researchers have intensely studied glomerular damage in chronic kidney disease 
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research, because not only is this the site of glomerular filtration, but also glomerular 
damage is a characteristic of chronic disease. However recent studies have suggested 
tubular damage is also a hallmark of chronic kidney disease and an indicator of disease 
progression and severity (Han, Ly, Tesch, Poronnik, & Nikolic-Paterson, 2018; 
Schelling, 2016). 
The presence of albumin in the urine is a hallmark of both acute and chronic 
kidney disease and can be used to determine if the state of the disease will progress to 
end-stage kidney disease (Astor et al., 2011; Looker et al., 2015). Early stages of chronic 
kidney disease show an increase of albuminuria and a decreased glomerular filtration rate 
(GFR) (Coresh, Astor, Greene, Eknoyan, & Levey, 2003) whereas evidence of 
glomerulosclerosis and renal interstitial fibrosis is an indication of severe chronic kidney 
disease that leads to end-stage renal disease (T. Lee, Shah, Leonard, Parikh, & Thakar, 
2018). In cases of evident glomerulosclerosis, there is an increase of endothelial damage 
and dysfunction, activation and proliferation of smooth muscle or mesangial cells, and 
injury to the podocytes (A Meguid El Nahas & Bello, 2005). Communication between 
cells via cytokines or growth factors leads to the increased deposition of extracellular 
matrix that leads to scarring of the glomerulus.  
Damage to the proximal tubules is also seen in chronic kidney disease. Damage to 
the proximal tubules is independent of the damage that occurs in the glomerulus. The 
proximal tubules are subjected to irreversible damage and undergo morphologic changes, 
such as loss of brush border and apical mitochondria followed by complete loss of tubular 
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epithelial cells, or whole tubules that occurs with interstitial fibrosis (Risdon, Sloper, & 
De Wardener, 1968; Rosenbaum, Mikail, & Wiedmann, 1967; Schelling, 2016).  
As scientists are becoming more aware of the damaging effects that are associated 
with chronic kidney disease, there is not only a growing need to investigate the 
complications associated with this disease to find a treatment to halt the disease 
progression but also because of the increased incidence of patients inflicted with chronic 
kidney disease.  
The number of patients diagnosed with chronic kidney disease is growing at an 
alarming rate and is a major concern for not only health-care professionals but also the 
diagnosed individuals and their care-takers. Due to the fact of the development of chronic 
kidney disease in diabetic patients significantly increases the mortality and morbidity 
rates along with health care costs world- wide (Roshan & Stanton, 2013). The health care 
costs are incurred to detect and manage chronic kidney disease, end-stage renal disease, 
and simultaneous management of comorbid conditions such as diabetes, congestive heart 
failure, and hypertension (V. Wang, Vilme, Maciejewski, & Boulware, 2016). 
Epidemiologically, there are several causes of chronic kidney disease with diabetes 
mellitus being the greatest contributor(Thakar, Christianson, Himmelfarb, & Leonard, 
2011). Although diabetes mellitus is heavily studied, the mechanism(s) behind the 
disease progression to a chronic kidney disease and ultimately end-stage renal disease 
(ESRD) remains least understood.  
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Diabetic Nephropathy 
Diabetic nephropathy is a serious microvascular complication of diabetes mellitus 
and is the leading cause of chronic kidney disease (Kanwar et al., 2011; Suarez et al., 
2013; Tervaert et al., 2010). Diabetic nephropathy is characterized by the early detection 
of albuminuria after diagnosis of diabetes mellitus (Suarez et al., 2013). However 
pathophysiological changes occur after prolonged exposure, such as hypertrophied 
glomeruli and tubules that is associated with increased thickening of the glomerular and 
tubular basement membranes that results from the excessive deposition of extracellular 
matrix (ECM) (Fioretto & Mauer, 2007; Kanwar et al., 2011).  Renal injuries that arise 
from diabetes mellitus whether its type 1 or type 2 result in a similar pathophysiological 
outcome (Fioretto & Mauer, 2007). Diabetic nephropathy is caused by prolonged 
exposure to hyperglycemia.  
 
Glucose Handling by Proximal Tubule Cells  
The kidney’s main function is to reabsorb and transport nutrients from the 
glomerular filtrate back into the blood to be used by other systems. Since the proximal 
tubule cells are responsible for reabsorbing roughly 90% of the nutrients such as glucose, 
amino acids, or salts in the ultra-filtrate, it’s important to understand how these cells 
respond to an increased level of glucose.  
The proximal tubule cell reabsorbs glucose via two mechanisms; sodium-glucose 
linked transporter (SGLT) and facilitated glucose transporter (GLUT) (Blantz & Singh, 
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2014; Y. J. Lee, Lee, & Han, 2007; Vallon & Thomson, 2012). Sodium-glucose linked 
transporter transports glucose in an insulin independent manner and is driven by a high-
flux low-affinity of glucose at the brush border of the apical membrane (Mather & 
Pollock, 2011). Facilitated glucose transporters are found at the apical and basolateral 
regions of the cell and can bi-directionally transport glucose across the cell membrane (Y. 
J. Lee et al., 2007) Similar to SGLTs, GLUTs are driven by the high-flux low affinity of 
glucose (Alsahli & Gerich, 2017; Y. J. Lee et al., 2007). Since the transport of glucose is 
insulin-independent, the proximal tubule cells are more susceptible to damage caused by 
high levels glucose, hyperglycemia.  
When glucose in the filtrate reaches approximately 10 mmol/L, the SGLTs and 
GLUTs become saturated and the maximal reabsorption rate has been met (Poudel, 
2013). Under these conditions, glucose in the urine can be detected. If the problem 
persists, damage to the proximal tubule cells will occur.  
Mechanisms of Hyperglycemia Damage in Proximal Tubule Cells 
There are several hypothesis of hyperglycemia induced damaged that have been 
intensely studied, as well been the main focus in clinical trials. There are several 
hypotheses about the mechanism as to how complications associated with diabetic 
nephropathy arise. One possible mechanism, activation of the polyol pathway, was shown 
to be the major player in complications associated with diabetic retinopathy (VAN 
HEYNINGEN, 1959). Several studies following the initial discovery of the role of the 
polyol pathway’s involvement in cataract formation in diabetic retinopathy have targeted 
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aldose reductase activity as a means of treatment. Since microvascular complications 
induced by diabetes mellitus are pathophysiologically similar in the retina and kidney, 
investigation into how activation of the polyol pathway leads to complications in diabetic 
nephropathy has been intensely studied (Das & Srivastava, 1985; Fowler, 2008). 
Once inside the proximal tubule cell, glucose can be metabolized by two different 
enzymes 1) hexokinase to form glucose-6-phosphate or 2) aldose reductase (ARK1B1) to 
form sorbitol (Kinoshita, 1990; Yabe-Nishimura, 1998). However hexokinase will 
become saturated as the glucose influx increases rendering aldose reductase the main 
means of glucose metabolism. This increased activity of aldose reductase leads to 
complications such as osmotic and oxidative stress (Michael Brownlee, 2005). 
Aldose reductase is the first and rate-limiting enzyme of the polyol pathway 
(Hodgkinson et al., 2001). Aldose reductase belongs to a family of NADPH 
oxidoreductases where there are three isoforms of the AKR1B in humans; AKR1B1, 
AKR1B10, and AKR1B15 (Cao, Fan, & Chung, 1998; Giménez-Dejoz et al., 2017; 
Taskoparan et al., 2017). Aldose reductase is a cytosolic, monomeric NAPDH-dependent 
oxidoreductase that metabolizes a wide variety of carbonyl molecules such as sugars, 
aldehyde metabolites, and ketones (Bohren, Bullock, Wermuth, & Gabbay, 1989). These 
enzymes are more efficient at reducing aromatic and aliphatic aldehydes but in 
hyperglycemic conditions will metabolize glucose to sorbitol (Cao et al., 1998; Zopf et 
al., 2009). Sorbitol dehydrogenase (SORD) is the second enzyme of the polyol pathway 
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and it oxidizes sorbitol to fructose using NAD+ as a cofactor (Gabbay, 1973; Schrijvers 
et al., 2004).  
 
Figure 1.1 Polyol Pathway. Adapted from (Brownlee. 2004).  
 
 
Evidence for the Role of the Polyol Pathway in Diabetic Complications 
Since sorbitol is unable to freely cross the cell membrane it accumulates within 
the cell leading to complications associated with microvascular diseases such as osmotic 
damage. The role of aldose reductase isoform, AKR1B1, in microvascular complications 
with diabetes was first found out in the mid- 1950’s. The early work of Dr. Van 
Heyningen set the stage of the role of the polyol pathway in microvascular complications 
associated with diabetes.  
In 1974, a group from London was trying to determine why genetically diabetic 
mice did not experience cataracts. It was concluded that these mice (and several other 
mice of different backgrounds) had a low level of aldose reductase activity in the lens, 
but when the activity was looked at in rats, there was an appreciable high amount of 
aldose reductase activity in a diabetic state (Varma, Mikuni, & Kinoshita, 1975), 
suggesting these rats experienced cataract formation when they were clinically diagnosed 
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as having diabetes. After several years of intensive investigations, researchers concluded 
the polyol pathway activation has some role in the onset of complications associated with 
hyperglycemia, the generations of inhibitors targeted at aldose reductase were in popular 
demand. 
However it wouldn’t be until a decade later that researchers studied the role of the 
polyol pathway in complications associated with diabetic nephropathy. Researchers 
concluded in diabetic induced mice treated with an aldose reductase inhibitor showed 
decreased levels of proteinuria (Beyer-Mears, Ku, & Cohen, n.d.; Cohen, 1986). These 
studies were the first to relate complications of diabetic nephropathy with activation of 
the polyol pathway.  
Shortly after Beyer-Mears study, another study looked directly at human proximal 
tubule cells response to hyperglycemia and if the polyol pathway was involved. This 
group of researchers concluded that human proximal tubule cells exposed to high levels 
of glucose (27.5 mM) for short periods of time had an increased accumulation of sorbitol 
and increased aldose reductase activity while no change in sorbitol dehydrogenase 
activity (Bylander & Sens, 1990). When the cells were treated with an aldose reductase 
inhibitor, sorbinil, there were diminished levels of sorbitol accumulation and aldose 
reductase activity suggesting the polyol pathway has a role in complications associated 
with diabetic nephropathy via intracellular accumulation of sorbitol.  
Since then there have been several studies supporting aldose reductase increased 
activation in hyperglycemic conditions and its role in diabetic mellitus complications 
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(Hodgkinson et al., 2001; Rusak, Misztal, Rusak, Branska-Januszewska, & Tomasiak, 
2017; Shah, Dorin, Sun, Braun, & Zager, 1997; Shukla, Pal, Sonowal, Srivastava, & 
Ramana, 2017). 
At the time of the initial studies of the polyol pathway and hyperglycemia, little 
was known about the polyol pathway enzymes and their roles in diabetic complications. 
Researchers knew the production of sorbitol was a driving force for microvascular 
complications in diabetes and when aldose reductase activity was inhibited complicated 
ceased. Since these first investigations, there have been several other aldose reductase 
isoforms discovered. However, their roles in diabetic complications are least understood. 
While the biological role of AKR1B10 is unknown however it has been shown to 
be involved in a wide variety of metabolic pathways such as retinoic acid (Gallego et al., 
2006) and is over expressed in several different types of cancer such as breast, 
endometrial, and or lung (Huang et al., 2016; Reddy et al., 2017).  
In 2014, the first study to investigate AKR1B10 involvement in complications of 
diabetes nephropathy was published. These researchers investigated the role of 
AKR1B10 in patients with type 1 diabetes mellitus but no signs of nephropathy, versus 
type 1diabetics with nephropathy, and healthy with no signs of type 1 or 2 diabetes. 
Under high glucose (20 mM) conditions there was a significant induction of AKR1B10 
protein levels in samples collected from patients with diabetic nephropathy in comparison 
to no induction in samples collected from healthy patients (Shaw, Yang, Millward, 
Demaine, & Hodgkinson, 2014).  
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Although the work by Shaw et al., 2014 were the first to demonstrate AKR1B10 
is induced by high glucose; no further research has been conducted on this enzyme’s 
expression in the kidney of diabetic nephropathy.  
Treatment for Diabetic Nephropathy 
In the initial discovery of aldose reductase in the microvascular complications 
associated with diabetes mellitus, there was a mass generation of inhibitors as a possible 
treatment. These inhibitors were either the competitive or noncompetitive type. Initial 
studies on aldose reductase biological properties demonstrated it was sensitive to long-
chain fatty acids which led to the development of the first aldose reductase inhibitor, 3,3-
tetramethyleneglutaric acid (TMG) (Jedziniak & Kinoshita, 1971). TMG was shown to 
inhibit aldose reductase in diabetic-induced rat lens and in the process cataract formation 
decreased. A couple years following, the establishment of a more potent aldose reductase 
inhibitor was produced; alrestatin (Gabbay, Spack, Loo, Hirsch, & Ackil, 1979) In 1981, 
the first clinical trial was conducted with diabetic neuropathy patients but was halted due 
to toxic effects of the inhibitor (Tsai & Burnakis, 1993).  
Several aldose reductase inhibitors have been produced and have shown to be an 
effective treatment in improving the complications of diabetes mellitus however due to 
adverse side-effects in clinical trials all but one aldose reductase inhibitor were 
discontinued from further trials. Epalrestat is the only aldose reductase inhibitor currently 
commercially available for treating complications associated with diabetes mellitus 
((Grewal, Bhardwaj, Pandita, Lather, & Sekhon, 2016). 
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Other Contributing Factors and Diabetic Nephropathy 
There are several risk factors that can lead to the disease progression of diabetes 
to diabetic nephropathy such as lifestyle, genetics, and environmental factors. Although 
several risk factors have been identified as playing a role in the disease progression to 
diabetic nephropathy, there are still several unidentified environmental risk factors that 
may also play a role in this disease progression. Up until recently, there has been more 
support that cadmium may have a role in the disease progression of diabetes to diabetic 
nephropathy. 
Cadmium Toxicity Causes Proximal Tubule Cell Damage 
 Cadmium is a heavy metal toxicant found naturally in the environment where 
exposures cause serious health effects in those exposed. This is a growing concern for 
those in the medical fields, government agencies, and the public since exposure can occur 
through several sources including diet and habit, burning of fossil fuels, and industrial 
mining to name a few (ASTDR). Individuals who smoke cigarettes obtain the majority of 
their cadmium exposure via tobacco smoke as this route of entry leads to an efficient 
absorption from the lungs, however the lungs are not the only site of Cd2+ insult (Garrett, 
Somji, Sens, Zhang, & Sens, 2011). Cadmium toxicity has also been shown to cause 
damaging effects in the skeletal system and kidneys.  
Sources of Cadmium Exposure 
 The general population is exposed to Cd2+ through three main sources; tobacco, 
food, and occupation. Cadmium exposure through inhalation of tobacco smoke occurs 
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because cadmium accumulates in the tobacco plant, Nicotiana tabacum and it generates 
levels of .5 to 2 μg of Cd2+ per cigarette (Ganguly, Levänen, Palmberg, Åkesson, & 
Lindén, 2018). Cadmium through this route of entry is in the form of cadmium oxide 
where it can be deposited in the lung tissue or absorbed into the systemic blood 
circulation. (Yue, 1992). 
 Contaminated soil is the main source of Cd2+ exposure in the population of non-
smokers. Agricultural and industrial activities have contributed to the alarming increase 
of contaminated soil.  Therefore whole grains, leafy vegetables, root vegetables and some 
seeds contain high amounts Cd2+ and account for 80% dietary source (Ganguly et al., 
2018). 
 The final source of Cd2+ toxicity is through occupational exposure. This typically 
occurs in industrial factories such as smelters, battery manufacturing, metal recovery 
factories, or production units for paint and pigment (Nair, DeGheselle, Smeets, Van 
Kerkhove, & Cuypers, 2013). 
As researchers and health officials recognize the possible effects Cd2+ toxicity can 
have on the human body, the more researchers have studied the damaging effects of this 
toxicant.   
Potential Mechanisms for Cadmium Cellular Damage 
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 Cadmium enters the body through the lungs or the gastrointestinal tract through 
tobacco smoke or food intake, respectively. Although the exact mechanism which cells 
uptake Cd2+ is unknown, it has been theorized that Cd2+uses similar transport systems as 
other  metals such as calcium, iron, zinc, and manganese due to their similar size  
(Clarkson, 1993; Satarug, 2018). These transport systems include divalent metal 
transporter 1 (DMT1), ZIP8, and ZIP14 (Girijashanker et al., 2008; Park, Cherrington, & 
Klaassen, 2002). However, if there is a restriction of iron, zinc, or calcium then this will 
lead to a greater absorption and accumulation of Cd2+ (Vesey, 2010), therefore nutritional 
state must be taken into consideration when studying the effects of Cd2+ toxicity and 
transport.  
 Once Cd2+ is absorbed it binds to high molecular weight proteins in the blood and 
is transported to the liver where it binds to and stimulates metallothionein synthesis 
(Järup, Berglund, Elinder, Nordberg, & Vahter, 1998). Metallothioneins are low 
molecular weight proteins that are widely distributed in the body. These proteins have a 
high cysteine content which allows them to have a high affinity for metals such as zinc, 
cadmium, mercury, copper, lead, and iron (Klaassen et al., 2009; Sabath & Robles-
Osorio, 2012) Although these metals have the capability of binding to metallothioneins, 
when Cd2+ is present it will displace other metals and bind to metallothioneins.  
After Cd2+ is bound to the metallothionein proteins, it is then transported back 
into blood where it is filtered by glomerulus and reabsorbed by proximal tubule cells of 
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the kidney. Expression of ZIP8 transporters at the apical membrane mediates the uptake 
of Cd2+ bound metallothionein complexes (Fujishiro, Yano, Takada, Tanihara, & 
Himeno, 2012; Satarug, 2018; Schneider et al., 2014).  Another possible mechanism of 
transport of Cd2+ bound metallothionein complexes into the kidney is by megalin whereas 
megalin mediates uptake of Cd2+ bound metallothionein via endocytosis (Wolff, 
Abouhamed, Verroust, & Thévenod, 2006).  After the Cd2+ bound metallothionein 
complexes are within the cell, they are degraded by endosomal and lysosomal 
mechanisms with the release of Cd2+causing programmed cell death. Since Cd2+ has a 
half-life of 10 – 30 years (Friberg, 1984; Järup et al., 2000) it easily accumulates within 
the proximal tubule cells rendering it more susceptible to cadmium toxicity (Edwards & 
Prozialeck, 2009).  
17 
 
The proximal tubule cells have a Cd2+ threshold of 150- 200 ug/g, exposure to 
anything of above these levels leads to polyuria, proteinuria and glucosuria (Järup et al., 
2000; Satarug, Haswell-Elkins, & Moore, 2000). As Cd2+ overloads the proximal tubule 
cells system, it can exert its toxic effects by activating pathways of the inflammatory 
response, oxidative stress, and genotoxicity.  
Figure 1.2 Schematic diagram of Cd2+ uptake, transport and urinary excretion. 
Adapted from (Satarug S. 2018).  
 
The first evidence of Cd2+ toxicity arose in 1955 in Japan where residents were 
exposed to low concentrations of Cd2+ through ingestion of contaminated rice developed 
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an outbreak of Itai-Itai disease, which translates to “it hurts – it hurts”. These exposed 
individuals were found to have renal tubular damage, osteomalacia, anemia and 
malabsorption (Nordberg, 2009). In another study, conducted specifically on middle-aged 
women in Sweden, found a connection between Cd2+ accumulation and renal injury. In 
this study the maximal Cd2+ accumulation individuals experienced, impaired tubular 
reabsorption, as evident by the presence of proximal tubule proteins in urine i.e. N-acetyl-
β-D-glucosaminidase (Akesson et al., 2005).   
Due to the health risks associated with Cd2+ exposure, regulations were created to 
prevent and monitor excessive toxicant contamination and exposure.  
Regulation of Cadmium Exposure 
As the toxic effects of Cd2+ exposure are becoming more evident, guidelines were 
established by federal health agencies. Occupational safety and health administration 
(OSHA) established set limits of Cd2+ exposure in the workplace. According to their 
guidelines, the permissible exposure limit is 5 μg/ m3  and National Institute of 
Occupational Safety and Health (NIOSH) has set an immediately dangerous to life and 
health level (IDLH) of 9mg/m3 (OSHA, 2012; NIOSH; 2012). 
 Cadmium exposure standards have also been set to protect the general population 
by several different government agencies. The U.S. Food and Drug Administration 
(FDA) has a set a .0005 mg/L of Cd2+ in bottled water, ASTDR has a set Cd2+ intake of  
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.1 μg/kg/day, EPA has set a Cd2+ dose from food at .001 mg/kg/day and .0005 mg/kg/day 
from water (ASTDR, 2013).  
 When regulations fail to exist for toxicants that are known to have adverse health 
effects, it can lead major health problems in the general population.   
Cadmium and Diabetic Nephropathy 
Evidence suggests early Cd2+ exposure may have a contributing factor to the onset 
and severity of diabetes mellitus. Although, there is contradictory evidence of the 
relationship between cadmium exposure and the risk of developing diabetes mellitus.  
Studies have shown elevated cadmium exposure was associated with a higher 
BMI, waist, and hip circumference in teenage females (Kim et al., 2015). These findings 
were supported by a study conducted on the indigenous people of the Torres Strait 
Islands. 32% of women between the ages of 30 and 50 had detectable levels of cadmium 
in their urine, 2 µg of cadmium per gram of creatinine (Haswell-Elkins et al., 2007) 
where normal levels are .26 µg of cadmium per gram of creatinine (ATSDR, 2013). 
In 2003, Schwartz et al. analyzed data from the National Health and Nutrition 
Examination Survey (NHANES) III (1988-1994) that involved 8772 adults, had shown 
increasing urinary cadmium levels were associated with an impaired fasting glucose 
(defined by ≥100 and < 126 mg/dl) and increased prevalence of type II diabetes 
(Schwartz, Il’yasova, & Ivanova, 2003).  
Similarly, Wallia et al. analyzed data from the National Health and Nutrition 
Examination Survey from 2005 to 2010 on 2398 patients 40 or older. Patients with a 
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higher exposure to cadmium were more susceptible to diabetes mellitus. Also, in 
individuals that were heavy smokers were more at a higher risk for diabetes mellitus 
(Wallia, Allen, Badon, & El Muayed, 2014).  
In another study conducted on a Thailand population exposed to cadmium 
contaminated food sources, individuals were initially tested for renal function, 
hypertension, diabetes, and urinary stones with follow-up tests completed 5 years later. It 
was concluded there were significant increases in tubular damage (detected by β2-
microglobulin urinary marker), urinary protein and serum creatinine, a decrease in 
glomerular filtration rate (Swaddiwudhipong et al., 2012). There were also significant 
increases in the prevalence of hypertension, diabetes mellitus, and urinary stones. 
However, there was no detection in individuals who reduced their Cd2+ exposure..  
There have been several studies that investigated cadmium toxicity on animal 
models with or without diabetes mellitus. Many have supported the same findings as 
what is observed in humans. For example, Prozialeck et al. found in rats given 
subcutaneous injections of cadmium increased urinary expression of Kim-1 (marker for 
proximal tubule damage), protein levels, glucose, and creatinine (Prozialeck et al., 2007). 
When observing toxicant damage from a diabetes mellitus stand-point, individuals 
diagnosed with type II diabetes mellitus were more prone to cadmium nephrotoxicity 
than those without diabetes mellitus suggestive of cadmium accumulation contributes to 
the development of diabetes mellitus (Afridi, Kazi, Brabazon, Naher, & Talpur, 2013). 
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All these studies support the hypothesis of individuals exposed to low levels of 
Cd2+ over a long duration of time, are more susceptible to the development of 
complications associated with diabetes mellitus and ultimately the disease progression to 
diabetic nephropathy. This could be due to the fact of both these toxicants target and 
induce damage to the proximal tubule cells of the kidney once an accumulation threshold 
is reached. When the system of the proximal tubule cell is reaching an overload of the 
amount of toxicant it can protect against and another toxicant is introduced, this will 
cause irreversible damage to the proximal tubule cell. It is because of this idea that at a 
given point in time the general population is exposed to more than one toxicant that 
researchers should investigate the damaging effects of a dual exposure on various organ 
systems.  
Hypothesis and Rationale 
This project tests the hypothesis that cadmium has a role in the onset of the 
complications associated with diabetic nephropathy through the activation of the aldose 
reductase isoform, AKR1B10. In this first study, the role of cadmium or high levels 
glucose exposure on the polyol pathway will be investigated in the human proximal 
tubule cell model system. Preliminary results from a global gene expression analysis 
revealed an induction of the aldose reductase isoform, AKR1B10, in human proximal 
tubule cells exposed acutely and chronically to cadmium (Garrett et al., 2010). The first 
aim of this project was to confirm AKR1B10 is induced by cadmium or hyperglycemia. 
Since AKR1B10 is a newly found isoform of aldose reductase family there is little data 
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on the physiological role of this enzyme so we needed to characterize the role of 
AKR1B10 in human proximal tubule cells exposed to the nephrotoxicants; cadmium or 
glucose. We also investigated if the other enzymes of the polyol pathway (aldose 
reductase isoforms, AKR1B1 and AKR1B15 or sorbitol dehydrogenase) were induced by 
cadmium or hyperglycemia in our human proximal tubule cell model.  
To further characterize the role of the polyol pathway involvement in diabetic 
nephropathy, sorbitol accumulation will be measured within human proximal tubule cells 
exposed to cadmium or hyperglycemia. Aldose reductase metabolizes glucose to sorbitol 
therefore sorbitol accumulation is an indication of aldose reductase activity. Also sorbitol 
accumulation promotes osmotic stress therefore the accumulation of this osmolyte causes 
the proximal tubule cell’s system to dysfunction ultimately leading to cellular death.  
The second aim of this project was to investigate and characterize the effects of a 
dual exposure of both cadmium and hyperglycemia on human proximal tubule cells. This 
aim is designed to mimic the effect that would be seen in the general population since 
there are exposures to more than one nephrotoxicant at one time. Therefore the polyol 
pathway genes, as measured in the first aim, will be measured to determine if pre-
exposure to cadmium toxicity will augment the effects seen in a hyperglycemia situation. 
Although there are several studies that explored the effects of cadmium or glucose 
toxicity in human diseases, no study has investigated these nephrotoxicants in an isolated 
situation to look at the effects of their combined exposure on the human proximal tubule 
cells.  
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The final aim of this study investigated the expression of glucose transporters and 
glucose utilization in the human proximal tubule cells. To ensure the current model is 
best suited for investigating the effects of cadmium and hyperglycemia toxicity, we 
characterized the uptake of glucose via glucose clearance from the media as well as 
measured the expression of glucose transporters in these cells.  
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CHAPTER I.II 
METHODS 
Cell Culture 
 There were two types of proximal tubule cells used in this study. One type was 
the primary proximal tubule cells or known as human proximal tubule (HPT) cells. They 
were isolated from healthy, normal sections of a human kidney. The other proximal cell 
type used was an immortalized cell called human telomerase reverse transcriptase 
(RPTEC/TERT1 (ATCC CRL-4031)) renal proximal tubule epithelial cells (RPTEC), 
referred to as RPTEC/TERT1 (ATCC CRL-4031) cells. These epithelial cells were 
immortalized with the human telomerase reverse transcriptase gene using the pLXSN 
vector, allowing these cells to have an infinite life-span.  
HPT were grown using serum-free conditions and collagen coated culture flasks 
as described previously (Detrisac et al., 1984; Kim et al., 2002). Stock cultures were fed 
growth media comprised of a 1:1 mixtures of Dulbecco’s modified eagle’s medium 
(DME) and Ham’s F-12 growth medium supplemented with selenium (5 ng/ml), insulin 
(5 µg/ml), transferrin (5 µg/ml), hydrocortisone (36 ng/ml), triiodothyronine (4 pg/ml) 
and epidermal growth factor (10 ng/ml). The cells were fed fresh-growth medium every 2 
days and were subcultured 1:2 at confluency (~8 days post subculture) using trypsin-
EDTA (.05% - .02%). RPTEC/TERT1 (ATCC CRL-4031) cells were obtained from the 
American Type Culture Collection, expanded according to recommended culture 
conditions, and aliquots were stored in liquid nitrogen.  
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 For the glucose studies, glucose was added to growth media that contained 
a 1:1 mixture of a glucose free DME and Ham’s-F12 such that the final glucose 
concentrations in the media were: 5.5, 7.5, 11, 16, 27.5, 36, 100 mM.   Unless otherwise 
mentioned the culture media had the same concentration of all aforementioned growth 
factors.   
RNA isolation and RT-qPCR 
Total RNA was purified from cultures of HPT or RPTEC/TERT1 (ATCC CRL-
4031) cells utilizing TRI Reagent (Molecular Research Center, Inc.) and quantified by 
spectrophotometry (Nanodrop).  100 ng of total RNA was subjected to cDNA synthesis 
using the iScript cDNA synthesis kit (Bio-Rad) for a final volume of 20 μL. Gene 
expression was measured with real-time reverse transcription polymerase chain reaction 
(RT-PCR) using primers of interest (see Table 1.2.1). Real time PCR was performed 
using SYBR Green (Bio-Rad) with 2 μL cDNA and .2 μM primers in a final volume of 
20 μL in the CFX96 Touch Real-Time detection system (Bio-Rad). SYBR Green 
fluorescence was used to monitor the amplification of the reaction and further analyzed 
by interpolation from a standard curve.  
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Gene Company Catalog No.  
AKR1B1 Qiagen QT00088648 
AKR1B10 Qiagen QT000668695 
   
   
SORD Biorad qHsaCED0044950 
TXNIP Biorad qHsaCED0043730 
   
Table 1.2.1 Primer Information 
Protein Isolation  
For the glucose studies, total protein was isolated from HPT cells using a 2% 
Sodium Dodecyl Sulfate (SDS) solution containing 50 mM Tris-HCL, pH 6.8 with 1% 
protease inhibitor cocktail (Sigma-Aldrich). Cell pellets were homogenized in the lysis 
buffer, boiled for 10 minutes and subjected to DNA shearing by sonication. Protein 
concentration was determined by BCA assay (Pierce). Stock samples were stored at -
80ºC.  
For the cadmium and glucose studies with RPTEC/TERT1 (ATCC CRL-4031) 
cells, total protein was isolated from the HPT and RPTEC/TERT1 (ATCC CRL-4031) 
cells using a RIPA lysis buffer containing protease inhibitors, PMSF, and sodium 
orthovandate (Santa Cruz). Cell pellets were homogenized in cold RIPA lysis buffer at a 
1:2 w/v ratio and incubated on ice, with orbital shaking for 30 minutes. The samples were 
then sonicated and centrifuged at 10,000g for 10 minutes at 4°C. The supernatant was 
collected in cold, separate tubes and subjected to BCA assay (Pierce) for protein 
quantification and stored -80ºC.  
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Western Blot Analysis 
 Protein expression was measured by Western blot techniques. Twenty µg protein 
was separated by SDS-Page using the TGX AnyKd SDS polyacrylamide gel (Bio-Rad). 
Samples contained equal amounts of protein and Laemmli buffer (Bio-Rad) containing β-
mercaptoethanol. The samples were then boiled for 5 minutes at 95ºC to reduce protein. 
Once samples were back to room temperature, they were loaded into the gel. Proteins 
were then transferred to a .2 µm PVDF membrane using a Trans-blot Turbo transfer 
apparatus (Bio-Rad). After transfer, the membranes were blocked with 5% nonfat dry 
milk in TBS-T for 90 minutes. Blots were incubated in 4ºC in the primary antibodies 
overnight on an orbital shaker. Table 1.2.1 has a list of all antibodies. 
Antibody Name Mw (kDa) Dilution Species Company Catalog No. 
AKR1B10 36 1:1000 Rabbit Abcam Ab192865 
AKR1B1 36 1:1000 Rabbit Abcam Ab62795 
BETA ACTIN 42 1:3000 Mouse Abcam Ab8226 
TXNIP 44  1:1000 Rabbit Abcam Ab188865 
Table 1.2.2 Antibody source.  
Glucose Utilization 
Glucose utilization by HPT and RPTEC/TERT1 (ATCC CRL-4031) cells 
exposed to 5.5, 7.75, 11, 16mM glucose was measured. Glucose utilization was measured 
using a glucose colorimetric assay kit II (Biovision). Briefly, media was collected 48 
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hours post-feed from HPT cells fed 5.5, 7.75, 11, 16 mM of glucose and frozen in -20°C. 
The media was thawed at room temperature where 300 μL of the collected media was 
centrifuged in a 10 kDa spin cut-off filter (Millipore). The flow through was collected 
and used to measure glucose utilization. A standard curve was prepared using a 1 
nmol/μL glucose standard to generate 0, 2, 4, 6, 8, and 10 nmol/well; bringing the final 
volume to 50 μL using the supplied assay buffer. A 50 μL/well glucose reaction mix was 
prepared with the following components: 46 μL Glucose Assay Buffer, 2 μL Glucose 
Enzyme, 2 μL Glucose substrate, according to supplier’s protocol. Reagents and samples 
were added to a 96 well plate and incubated for 30 minutes at 37°C, protected from light. 
The absorbance was measured at 450 nm on Biotek FLx800 plate reader.  
Sorbitol Assay 
Sorbitol accumulation in the HPT and RPTEC/TERT1 (ATCC CRL-4031) cells 
was measured using a D-sorbitol colorimetric assay kit (Biovision). Briefly, HPT cells 
exposed to 5.5, 7.75, 11, 16 mM glucose concentrations were harvested in nuclease-free 
water and stored at -80°C until used. HPT cells were thawed at room temperature, 
subjected to brief sonication, and centrifuged at 4°C at 13,200 rpm for 10 minutes. 
Supernatant was used for sorbitol accumulation measurements. A standard curve was 
prepared using a 1 nmol/μL sorbitol standard to generate 0, 2, 4, 6, 8, and 10 nmol/well; 
bringing the final volume to 50 μL using the supplied assay buffer. A 50 μL/well glucose 
reaction mix was prepared with the following components: 36 μL sorbitol assay buffer, 2 
μL sorbitol Enzyme, 2 μL sorbitol probe, 10 μL sorbitol developer, according to 
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supplier’s protocol. Reagents and samples were added to a 96 well plate and incubated 
for 30 minutes at 37°C, protected from light. The absorbance was measured at 570 nm on 
Biotek FLx800 plate reader. 
Cell Proliferation Assay 
Cell viability and proliferation was measured in HPT and RPTEC/TERT1 (ATCC 
CRL-4031) cells exposed to 5.5, 7.75, 11, 16 mM glucose using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Aldrich, MO). For cell 
proliferation, confluent cultures were split at a seeding density of ~20,000 cells per well 
into 6 well plates. Starting on day 2 post-seed, cells were treated with the different 
glucose concentrations. Day 3 post-seed, 40 μL of MTT reagent (5 mg/ml) was added to 
each well. One well containing no cells but media with MTT reagent was included in the 
analysis for the control. Plates were incubated for 3.5 hours at 37°C, followed by multiple 
(3x) PBS washes. 1 ml of acidic propanol was added to each well and placed on orbital 
shaker for 5 minutes, covered in tinfoil. Each well was mixed well then 200 μL of sample 
was added to a 96 well assay plate (flat bottom), done in triplicate.  The optical density 
was immediately measured at 570 nm on a BioTek FLx800 plate reader (BioTek 
Instruments INC, Winooski, VT). The final optical density readings were subtracted from 
blank and used to calculate cell proliferation. Values were read every day for 12 days.  
For cell viability measurements, confluent cultures were split at a seeding density 
of 300,000 cells per well into 6 well plates. Once confluent and doming, cells were then 
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exposed to the various concentrations of glucose. Day 2 post-treatment (24 hour glucose 
exposure), completed the MTT cell viability assay similar to the protocol for cell 
proliferation.  
Transient Knockdown of AKR1B10 
AKR1B10 expression was silenced in HPT and RPTEC/TERT1 (ATCC CRL-
4031) using a siRNA (Qiagen) and lipofectamine methods. Cells were seeded at 
~800,000 cells per well in a 6-well plate. 24 hours post-seed, a solution containing a 
siRNA for AKR1B10 and TransIT-X2 transfection reagent in serum- free medium was 
added to each well for final concentration of 20 µM and 50 nM, respectively 
(siRNA:TransIT complexes formed). 250 µL siRNA and transfection solution was added 
to each well in a drop-wise fashion. The plate was gently rocked back-and-forth and from 
side-to-side to evenly distribute the siRNA:TransIT complexes. The plates were 
incubated for 48 hours prior to treating with 5.5, 7.5, 11, or 16 mM glucose 
concentrations for 24 hours.  
Statistical Analysis 
 All experiments were performed either in triplicate or duplicate and the results 
were expressed as the standard error of the mean. Data sets were subjected to statistical 
analyses using GraphPad Prism® software. Statistical analyses performed was separate 
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variance t-tests, ANOVA with Tukey or Dunnett’s post-hoc testing. The level of 
significance was *p<.05, **p<.01, ***p<.001.  
Microarray Analysis 
Gene expression analysis was performed by Biomedical Genomics Center at the 
University of Minnesota (Minneapolis, MN). Isolation of total RNA was completed using 
a Qiagen RNeasy Mini Kit (Qiagen, CA) according to manufacturer’s instructions. A 
total of 100 ng of RNA was used for Genome wide expression which was determined 
using a Human HT-12v4 Expression BeadChip array (Illumina, CA) (discontinued in 
2016). Briefly, RNA was amplified and biotin-labeled using a labeling kit recommended 
by Illumina. The labeled RNA (cRNA) was quantitated using a Quant-iT RiboGreen 
RNA assay kit. cRNA was normalized and hybridized to the Illumina HT-12v4.0 
BeadChips. Probes are then detected using Cy3-Streptavidin for differential detection of 
signals. Images from the BeadChips are then analyzed using Illumina’s GenomeStudio 
Gene Expression Module. The data output was analyzed for differentially expressed 
genes by the Bioinformatics core facility at the University of North Dakota School of 
Medicine and Health Science. Differentially expressed probe sets (DEGs) were identified 
using empirical Bayes method and p-values adjusted using false discovery rate. R 
programming language and SAS JMPH software was used to analyze data.  
CHAPTER I.III 
RESULTS 
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Expression of AKR1B1, AKR1B10, SORD in Cd2+ Exposed HPT and 
RPTEC/TERT1 (ATCC CRL-4031) cells 
Results from a global gene microarray expression analysis completed on HPT 
cells exposed to various concentrations of Cd2+ for 24 hours (acute) or 13 days (chronic) 
showed an induction AKR1B10. RPTEC/TERT1 (ATCC CRL-4031) were also exposed 
to various concentrations of Cd2+ for 24 hours (acute) or 13 days (chronic) and were 
analyzed for AKR1B1, AKR1B10, SORD expression. The results from both the HPT and 
RPTEC/TERT1 (ATCC CRL-4031) were compared to each other to determine if Cd2+ 
exposures have the same effect on the polyol pathway in immortalized proximal tubule 
cells as primary proximal tubule cells. 
The expression of aldose reductase genes, AKR1B1 and AKR1B10 was measured 
to confirm the results of the global gene microarray of Cd2+ exposed HPT cells. Real-
time PCR was performed in the human proximal tubule cells exposed acutely or 
chronically to Cd2+. Both AKR1B1 and AKR1B10 expression was found to be 
significantly induced in HPT cells exposed to 27 and 45 µM Cd2+ for 24 hours (acute) 
(Figure 1.3.1. A, B). Acute Cd2+ exposures had no effect on SORD expression (Figure 
1.3.2. C). Western blot analysis showed AKR1B10  protein levels were also induced by 
Cd2+ exposures whereas AKR1B1 were not (Figure 1.3.1. C, D ). 
Similarly, AKR1B1 and AKR1B10 expression was found to be significantly 
induced in HPT cells exposed to 9 and 27 µM Cd2+ for 13 days (chronic) (Figure 1.3.2. 
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A, B). Chronic Cd2+ exposures had no effect on SORD expression (Figure 1.3.2. C). 
Western blot analysis showed AKR1B10  protein levels were also induced by Cd2+ 
exposures whereas AKR1B1 were not (Figure 1.3.2. C, D).  
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Figure 1.3.1 AKR1B1 and AKR1B10 expression is induced by acute exposures to 
Cd2+ in HPT cells.  RT-PCR analysis of AKR1B1 (A), AKR1B10 (B), and SORD (E) in 
HPT cells exposed to Cd2+ for 24 hours expressed as a fold change normalized to β- 
actin. Western blot analysis of AKR1B1 (C) and AKR1B10 (D) proteins in HPT cells 
exposed to Cd2+ for 24 hours. RT-PCR results represent ±SEM of triplicate. *p<0.05, 
**p<0.01, ***p<0.001 
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Figure 1.3.2 AKR1B1 and AKR1B10 mRNA expression is induced by chronic 
exposures to Cd2+ in HPT cells.  RT-PCR analysis of AKR1B1 (A), AKR1B10 (B), and 
SORD (E) in HPT cells exposed to Cd2+ for 13 days expressed as a fold change 
normalized to β- actin. Western blot analysis of AKR1B1 (C), AKR1B10 (D) proteins in 
HPT cells exposed to Cd2+ for 13 days. RT-PCR results represent ±SEM of triplicate. 
*p<0.05, **p<0.01, ***p<0.001. 
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As a means to compare and determine Cd2+ toxicity between a primary and an 
immortalized proximal tubule cell model, the expression of AKR1B1, AKR1B10, and 
SORD was measured in the RPTEC/TERT1 (ATCC CRL-4031) cells exposed acutely or 
chronically to Cd2+.  
 Similar to the HPT cells, RPTEC/TERT1 (ATCC CRL-4031) cells showed 
appreciable inductions of the AKR1B10 but not AKR1B1 and SORD by Cd2+ toxicity 
(Figure 1.3.3). Cd2+ concentrations had to be adjusted because RPTEC/TERT1 (ATCC 
CRL-4031) cells were more sensitive to Cd2+ toxicity induced cell death.AKR1B1 and 
SORD expression was also unaffected by chronic exposures to  Cd2+ toxicity but 
AKR1B10 is significantly induced at the mRNA levels (Figure 1.3.4 B) and there is also 
an increase in protein expression (Figure 1.3.4 D).  
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Figure 1.3.3 AKR1B1 and AKR1B10 expression is induced by acute exposures to 
Cd2+ in RPTEC/TERT1 (ATCC CRL-4031) cells.  RT-PCR analysis of AKR1B1 (A), 
AKR1B10 (B), and SORD (C) in RPTEC/TERT1 (ATCC CRL-4031) cells exposed to 
Cd2+ for 24 hours expressed as a fold change normalized  to β- actin. Western blot 
analysis of AKR1B1 (C) and AKR1B10 (D) in RPTEC/TERT1 (ATCC CRL-4031) cells 
exposed to Cd2+ for 24 hours. RT-PCR results represent ±SEM of triplicate. *p<0.05, 
**p<0.01, ***p<0.001. 
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Figure 1.3.4 AKR1B1 and AKR1B10 expression is induced by chronic exposures to 
Cd2+ in RPTEC/TERT1 (ATCC CRL-4031) cells.  RT-PCR analysis of AKR1B1 (A), 
AKR1B10 (B), and SORD (E) in RPTEC/TERT1 (ATCC CRL-4031) cells exposed to 
Cd2+ for 13 days expressed as a fold change normalized to β- actin. Western blot analysis 
of AKR1B1 (C) and AKR1B10 (D) proteins in RPTEC/TERT1 (ATCC CRL-4031) cells 
exposed to Cd2+ for 13 days. RT-PCR results represent ±SEM of triplicate. *p<0.05, 
**p<0.01, ***p<0.001. 
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Since the expression of the aldose reductase enzymes was induced by Cd2+, it was 
determined if other metals studied by this lab had an effect on these enzymes as well. 
Measured the expression levels of AKR1B1, AKR1B10, and SORD in HPT cells acutely 
exposed to 100 µM As3+. Starting at 8 hours post-exposure (recovery) to 100 µM As3+, 
there is a 2.5 fold induction of AKR1B1 and AKR1B10 with no significant induction of 
SORD (Figure 1.3.6 A, B, C, respectively). The induction of AKR1B1 slowly regressed 
back to control levels by 48 hours post-exposure. On the other hand, AKR1B10 reached 
maximum induction (3.5 fold induction) by 12 hours post-exposure.  
Figure 1.3.5 AKR1B10 and AKR1B10 expression is induced by acute exposures to 
As3+ in HPT cells.  RT-PCR analysis of AKR1B1 (A) and AKR1B10 (B) in HPT cells 
exposed to As3+ for 4 hours expressed as a fold change normalized to β- actin. RT-PCR 
results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001. 
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Preliminary Glucose Studies on Primary Human Proximal Tubule Cells 
Since most studies investigating diabetes mellitus use non-physiological relevant 
concentrations of glucose in relation to the disease, a range of glucose concentrations was 
used from 5.5 to 100 mM. It was determined what glucose concentrations primary or 
immortalized proximal tubule cells can tolerate.  
 Initially, when trying to determine which glucose concentrations to use to study 
the effects of hyperglycemia on primary HPT cells a range from 7.5 to 40 mM glucose 
was used. Primary HPT cells exposed to the 7.5, 15, 22.5, 37.5 mM glucose for 7 days. 
There was no noticeable cell death when cell morphology was observed under a phase-
contrast microscope. AKR1B1 expression was induced 1.4, 1.3, 2.4 fold by 15, 22.5, 37.5 
mM glucose, respectively whereas AKR1B10 4.5, 2.5, 2 fold induction by 15, 22.5, 37.5 
mM glucose, respectively (Figure 1.3.6 A, B). Since this was a pilot study to test the 
tolerance concentrations of glucose in primary HPT cells, protein analysis was not 
conducted.  
41 
 
 
Figure 1.3.6 Preliminary results of AKR1B1 and AKR1B10 expression in HPT cells 
exposed to various concentrations of glucose.  RT-PCR analysis of AKR1B1 (A), and 
AKR1B10 (B) in HPT cells exposed to 7.5, 15, 22.5, 37.5 mM glucose expressed as a 
fold change normalized to control. RT-PCR results represent ±SEM of triplicate. 
*p<0.05, **p<0.01, ***p<0.001 
 
In another pilot study, it was determined if the feeding schedule needed to be 
adjusted for the optimal results. The feeding schedule of treatments is an important player 
in the resulting effects. Typically, cultured cells are fed every other day. It was tested 
how the primary or immortalized HPT cells handled a longer feeding schedule; fed every 
3 days, with higher dosages of glucose.  
Primary HPT cells were exposed and continuously passaged in higher glucose 
concentrations for 24 days. Also, the feeding schedule was changed from 2 days to 3. 
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Although the cells were able to handle the increased glucose concentrations, there was an 
increased production of lactate as seen in the color change of the media.   
 
Figure 1.3.8 Preliminary results of AKR1B1 and AKR1B10 expression in 
RPTEC/TERT1 (ATCC CRL-4031) cells exposed to various concentrations of 
glucose every 3 days.  RT-PCR analysis of AKR1B1 (A) and AKR1B10 (B) in 
RPTEC/TERT1 (ATCC CRL-4031) cells exposed to 5.5, 16, 27.5, 100 mM glucose 
expressed as a fold change normalized to control. RT-PCR results represent ±SEM of 
triplicate. *p<0.05, **p<0.01, ***p<0.001 
 
 
 
Expression of AKR1B1, AKR1B10, SORD in High Glucose Exposed HPT and 
RPTEC/TERT1 (ATCC CRL-4031) cells 
 AKR1B10 is an isoform of the aldose reductase, AKR1B1, however the effects of 
hyperglycemia on this alternative isoform are not known. In order to determine if 
hyperglycemia induced the expression of AKR1B1, AKR1B10, and SORD in HPT and 
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RPTEC/TERT1 (ATCC CRL-4031) cells, confluent HPT or RPTEC/TERT1 (ATCC 
CRL-4031) cells were exposed to 5.5, 7.5 or 7.75, 11, or 16 mM glucose concentrations 
for 8 days then passaged and continuously exposed to various concentrations of glucose 
for another 8 days (P2). This process was repeated twice, with the cells in the final 
passage labeled as P3 and having a total glucose exposure of 24 days.  
AKR1B1 expression is not induced by increasing glucose concentrations in 
primary HPT cells (Figure 1.3.9 A).  
AKR1B10 expression had a 2 fold induction in 7.5 and 11 mM and a 3.5 fold 
inductions in HPT cells exposed to glucose for 8 days (P1).  AKR1B10 expression was 
maximally induced in HPT cells by 11 and 16 mM glucose in a 16 day exposure (P2) and 
after 24 days (P3) of glucose exposure, AKR1B10 expression was only induced 2.7 fold 
by 16 mM glucose (Figure 1.3.9 B).  
Glucose exposure had a minimal effect on SORD expression. In an 8 day (P1) 
exposure, 7.5, 11, 16 mM glucose induced SORD by 1.5 fold. There was no induction of 
SORD expression in 16 (P2) or 24 (P3) day glucose exposure (Figure 1.3.9 E). 
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Figure 1.3.9 AKR1B1 and AKR1B10 expression is induced in HPT cells exposed 
and passaged in glucose.  RT-PCR analysis of AKR1B1 (A), AKR1B10 (B), and SORD 
(C) in HPT cells exposed to 5.5, 7.5, 11, 16 mM glucose expressed as a fold change 
normalized to β- actin. Western blot analysis of AKR1B1 (D) and AKR1B10 (E) proteins 
in HPT cells exposed to glucose. RT-PCR results represent ±SEM of triplicate. *p<0.05, 
**p<0.01, ***p<0.001.  
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The activation of the polyol pathway in response to glucose toxicity was 
measured and compared to the RPTEC/TERT1 (ATCC CRL-4031) cells exposed and 
passaged in the same concentrations of glucose as HPT cells; 5.5, 7.5, 11, 16 mM.   
AKR1B1, AKR1B10, SORD expression was not induced by glucose in 
RPTEC/TERT1 (ATCC CRL-4031) cells (Figure 1.3.10 A, B, C).  
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Figure 1.3.10 AKR1B1, AKR1B10, SORD expression is not induced in 
RPTEC/TERT1 (ATCC CRL-4031) cells exposed and passaged in glucose.  RT-PCR 
analysis of AKR1B1 (A), AKR1B10 (B), and SORD (C) in RPTEC/TERT1 (ATCC 
CRL-4031) cells exposed to 5.5, 7.5, 11, 16 mM glucose expressed as a fold change 
normalized to control. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, 
***p<0.001 
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Glucose utilization in HPT and RPTEC/TERT1 (ATCC CRL-4031) cells exposed to 
glucose 
 Glucose utilization was measured in HPT and RPTEC/TERT1 (ATCC CRL-
4031) cells exposed to glucose for 48 hours. This measurement correlated with the 
glucose clearance by these cells since they were fed every other day.  
 Media was collected on every feed day from HPT cells exposed to 5.5, 7.5, 11, 16 
mM glucose for 8 days. Figure 1.3.11 represents two different measurements of glucose 
utilization by the HPT cells. D2 and D7 stands for day 2 and 7 of feeding, respectively. 
48 hours post feed, media was collected from the flask with HPT cells and subjected to 
glucose analysis by the glucose assay. These measurements are critical not only to ensure 
the HPT cells are metabolizing and transporting the glucose but also to estimate the 
amount of glucose being metabolized.  
 In both D2 and D7, HPT cells metabolized all of the glucose in 5.5 and 7.75 mM, 
97% of the glucose in 11 mM, 87% of the glucose in 16 mM media (Figure 1.3.11). Since 
the earliest measurement of glucose utilization was 48 hours post-feed, a similar 
experiment was conducted. HPT cells were exposed to 5.5, 7.75, 11, 16, 27.5, 100 mM 
glucose for 24 or 48 hours and glucose utilization was measured. At both time points, 
nearly all the glucose had been metabolized (Figure 1.3.12 A and B).  
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Figure 1.3.11 Glucose utilization by HPT cells exposed to glucose for 8 days.  
Glucose utilization in HPT cells exposed to 5.5, 7.5, 11, or 16 mM glucose for 8 days 
expressed as mM. Results represent ±SEM of triplicate.  
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Figure 1.3.12 Glucose utilization by HPT cells exposed to glucose for 24 or 48 hours.  
Glucose utilization by HPT cells exposed to 5.5, 7.5, 11, 16, 27.5, 100 mM glucose for 24 
(A) or 48 (B) hours expressed as mM. Results represent ±SEM of triplicate. 
 
Intracellular sorbitol accumulation in HPT and RPTEC/TERT1 (ATCC CRL-4031) 
cells exposed to glucose 
In a state of hyperglycemia, activation of the aldose reductase enzymes of the 
polyol pathway leads to the production of increased intracellular sorbitol accumulation. 
mRNA and protein levels showed an increased expression levels of AKR1B1 and 
AKR1B10, intracellular sorbitol measurements were made as a means to determine 
enzyme activity. 
Intracellular sorbitol measurements were made in primary HPT cells exposed to 
5.5, 7.75, 11, 16, 27.5, 100 mM glucose for 8 days and fed every other day. There is a 3-
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fold induction of intracellular sorbitol accumulation when HPT cells are exposed to 7.75 
mM glucose for 8 days as compared to the control (5.5 mM) and a 10 to 25-fold 
induction as the glucose concentration is increased.  
Sorbitol accumulation can be seen as early as 24 hours in HPT cells exposed to 
various concentrations of glucose. At a 24-hour exposure, HPT have a significant 
accumulation of sorbitol from 11 to 100 mM glucose (Figure 1.3.12 A). Similarly, at 48-
hour glucose exposure, there is a significant accumulation of sorbitol starting at 11 mM 
glucose (Figure 1.3.12 B) 
When measurements for sorbitol accumulation were taken in RPTEC/TERT1 
(ATCC CRL-4031) cells exposed to the same conditions as the HPT cells, there were no 
sorbitol accumulation (data not shown).  
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Figure 1.3.13 Intracellular sorbitol accumulation is increased in HPT cells with 
increased glucose concentration in an 8-day exposure.  Intracellular sorbitol 
measurements in HPT cells exposed to 5.5, 7.5, 11, 16, 27.5, 100 mM glucose for 8 days 
expressed as nmol/10^6 cells. Results represent ±SEM of triplicate. *p<0.05, **p<0.01, 
***p<0.001 
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Figure 1.3.14 Intracellular sorbitol accumulation is increased in HPT cells with 
increased glucose concentration in 24 or 48-hour exposure.  Intracellular sorbitol 
measurements in HPT cells exposed to 5.5, 7.5, 11, 16, 27.5, 100 mM glucose for 24 (A) 
or 48 (B) hours expressed as nmol/10^6 cells. Results represent ±SEM of triplicate. 
*p<0.05, **p<0.01, ***p<0.001 
 
Knock-down of AKR1B10 Attenuates Sorbitol Accumulation in HPT Cells Exposed 
to Glucose 
Since AKR1B10 was more sensitive to glucose toxicity, it was determined if a 
transient knock-down of AKR1B10 would attenuate sorbitol accumulation seen in HPT 
cells exposed to glucose.  Previous publications from this lab has showed knock-down of 
AKR1B1 by an inhibitor also showed a reduction of sorbitol accumulation but since little 
was known of AKR1B10 isoform and glucose toxicity, it needed to be investigated.  
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In HPT cells that were transiently transfected with a siRNA targeted for 
AKR1B10 and exposed to 5.5, 7.75, 11, 16 mM glucose for 24 hours showed a 
significant reduction in sorbitol accumulation (Figure 1.3.15 B).  
 
Figure 1.3.15 Intracellular sorbitol accumulation is decreased in HPT cells with 
AKR1B10 knock-down. RT-PCR analysis of AKR1B10 in AKR1B10 knock-down HPT 
cells  (A) exposed to 5.5, 7.5, 11, 16 mM glucose for 24 hours expressed as a fold change 
normalized to ACTB. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, 
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***p<0.001. Intracellular sorbitol measurements in AKR1B10 knock down HPT cells 
(B) exposed to 5.5, 7.5, 11, 16 mM glucose for 24 hours expressed as nmol/10^6 cells. 
Results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001 
 
Exposures to Hyperglycemic Conditions had no Effect on HPT Cell Proliferation or 
Viability 
 Hyperglycemia conditions had no effect on both the cell viability and 
proliferation. For cell proliferation, cells were seeded at a small percentage (1:100) such 
that they wouldn’t reach a growth plateau until 8 days or later. The growing cells exposed 
to 5.5, 7.5, 11, 16 mM glucose had no decrease in cell growth (Figure 1.3.16). For cell 
viability, confluent cultures (~8 days post-seed) were treated with the same 
concentrations of glucose previously mentioned. There was no cell death in response to 
the hyperglycemic conditions (Figure 1.3.17). 
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Figure 1.3.16 Cell proliferation in HPT cells exposed to hyperglycemia. Cell 
proliferation curves for HPT cells exposed to 5.5, 7.5, 11, 16 mM glucose for 6 days 
(measurements were taken starting day 4 post-seed).  The glucose treatments had no 
effect on HPT cell proliferation.  
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Figure 1.3.17 Cell viability in HPT cells exposed to hyperglycemia. HPT cells 
exposed to 5.5, 7.5, 11, or 16 mM glucose over a 8 day period had no changes in cell 
viability.  
 
Glucose Transporters absent in primary and immortalized kidney cell model 
systems 
 There have been reports of increased glucose transporter expression when 
exposed to high glucose concentrations therefore the expression levels of the sodium 
coupled glucose and facilitated glucose transporters based on the effects of glucose 
exposures in HPT and RPTEC/TERT1 (ATCC CRL-4031) cells was measured 
(Rahmoune et al., 2005; Umino et al., 2018).  
 In both HPT and RPTEC/TERT1 (ATCC CRL-4031) cells exposed and passaged 
in 5.5, 7.5/7.75, 11, and 16 mM glucose showed very little to no expression of SGLT1 
57 
 
(Figure 1.3.18 A), SGLT2 (Figure 1.3.18 B), and GLUT2. Other kidney cell models; 
RPTEC/TERT1 (ATCC CRL-4031), HK2, HK2-MT3, HPT-3, HPT-4, HPT-5, and 
whole kidney systems were tested for the expression of these transporters. Whole kidney 
sample had the highest expression of all SLC5A1 and SLC5A2 transporters (Figure 
1.3.18 A, B). 
 
Figure 1.3.18 SLC5A1 and SLC5A2 expression in various kidney samples. RT-PCR 
analysis of SLC5A1 (A) and SLC5A2 (B) in various kidney samples grown in 2012 or 
HPT-4 cells exposed to 5.5, 7.75, 11, 16 mM glucose for 8 days. Data expressed as fold 
change normalized to whole kidney 
 The expression of GLUT2 in the same set of kidney samples as in Figure 1.3.18 is 
not shown because the expression was so low or not detected in some of the samples.   
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HPT Cells do not Elicit an Additive Response to the Combine Glucose and Cd2+ 
Exposure 
Using in vitro model systems to study diseases helps to understand an isolated 
response that may occur due to exposures to a single toxicant or drug. Since the general 
population is exposed to more than one toxicant at time and there has been more support 
of cadmium toxicity having a role in diabetic nephropathy, the effects of a combined 
glucose and cadmium exposure was determined on HPT cells. RPTEC/TERT1 (ATCC 
CRL-4031) cells were not used for this part of the study since they didn’t respond to the 
glucose toxicity.  
HPT cells were exposed to low levels of Cd2+ (4.5 or 9 µM) for 72 hours then 5.5, 
7.75, 11, or 16 mM glucose was added for a combined exposure of 48 hours. There are 
significant inductions of both AKR1B1 and AKR1B10 in HPT cells exposed separately 
to glucose or Cd2+only. Also both AKR1B1 and AKR1B10 are induced by the combined 
exposure of Cd2+ and glucose however the response in not additive to what is seen by 
separate toxicant exposure (Figure 1.3.19 A and B).  
Intracellular sorbitol accumulation was also measured in HPT cells exposed to 
both cadmium and hyperglycemia. Although there is a significant induction of sorbitol 
accumulation in HPT exposed to hyperglycemic conditions for 48 hours, there is not an 
increased accumulation of sorbitol when exposed to both cadmium and hyperglycemic 
conditions (Figure 1.3.20). 
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Figure 1.3.19 AKR1B1 and AKR1B10 expression is induced by combined exposures 
to Cd2+ and Glucose in HPT cells.  RT-PCR analysis of AKR1B1 (A) and AKR1B10 
(B) in HPT cells exposed to 4.5 or 9 µM Cd2+ for 72 hours then added 5.5, 7.5, 11, 16 
mM glucose for a combined exposure for 48 hours. Data expressed as a fold change 
normalized to control. Western blot analysis of AKR1B1 (D) and AKR1B10 (E) proteins 
in HPT cells exposed to 4.5 or 9 µM Cd2+ for 72 hours then added 5.5, 7.5, 11, 16 mM 
glucose for a combined exposure for 48 hours. RT-PCR results represent ±SEM of 
triplicate. *p<0.05, **p<0.01, ***p<0.001 
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Figure 1.3.20 Intracellular sorbitol accumulation is increased in HPT cells in a 
combined exposure to Cd2+ and Glucose.  Intracellular sorbitol measurements in HPT 
cells HPT cells exposed to 4.5 or 9 µM Cd2+ for 72 hours then added 5.5, 7.5, 11, 16 mM 
glucose for a combined exposure for 48 hours. Data expressed as nmol/10^6 cells. 
Results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001 
 
Global Gene Analysis on Primary Human Proximal Tubule Cells Exposed to High 
Glucose concentrations for 24 days (P3) 
The disease etiology of diabetic nephropathy is highly complicated and not 
subjected to a single cause. There are numerous contributors to the onset and progression 
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of the disease. With this in mind, to investigate what other pathways or genes that may be 
activated in response to glucose toxicity in HPT cells, HPT cells that were passaged and 
exposed to glucose for 24 days (P3) was subjected to global gene analysis.  
Results from the global microarray had shown little gene induction although, 
there was one gene significantly induced in the 16 mM glucose compared to 5.5 mM 
(control). This gene was thioredoxin-interacting protein (TXNIP). TXNIP is an oxidative 
stress marker that binds and inhibits thioredoxin protein promoting oxidative stress.   
To confirm the microarray data, TXNIP expression was measured in HPT cells 
exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. In the first passage, there is a 50-
fold induction of TXNIP expression at the mRNA level in HPT cells exposed to 16 mM 
glucose for 8 days. In the later passages, TXNIP is still significantly induced by the 
glucose exposures just not as significant as the first passage (Figure 1.3.21). 
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Figure 1.3.21 TXNIP expression is induced in HPT cells exposed and passaged in 
glucose.  RT-PCRand protein analysis of TXNIP in HPT cells exposed and passaged in 
5.5, 7.5, 11, 06 16 mM glucose. Data expressed as a fold change normalized to ACTB. 
RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001 
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CHAPTER I.IV 
DISCUSSION 
Establishing a Proper Model for Investigating Diabetic Nephropathy  
Diabetic nephropathy is a major complication in individuals stricken with diabetes 
mellitus. Although there have been several pathophysiological insights there still remains 
a successful treatment for inhibiting the disease progression to the onset of more severe 
complications such as fibrosis. This is partly due to complicated nature of the disease 
with several contributing factors that have a role in the disease etiology.  The main new 
findings of this study that will contribute to the diabetic nephropathy field are the roles of 
AKR1B10 in glucose toxicity but the role of cadmium induced toxicity in contributing to 
the disease onset. With the exception of one publication from Shaw et al.2014 AKR1B10 
hasn’t been studied in the context of diabetes nephropathy or cadmium induced diseases 
therefore this study will help in the development of new treatments to target AKR1B10 
for both diseases. This study is also the first to investigate the effects the combined 
effects of cadmium and glucose toxicity and the usage of a human primary cell model 
system to characterize complications of diabetic nephropathy. 
Most studies investigating or characterizing the pathophysiology of cell model 
systems in hyperglycemic conditions as a means to better understand complications 
associated with diabetes mellitus have used non-physiological relevant concentrations of 
glucose. Therefore to properly investigate the glucose handling by proximal tubule cells 
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of the kidney and how hyperglycemia induces damage, we had to test multiple glucose 
concentrations and conditions for this study.  
  Since diabetic nephropathy is a progressive disease, kidney cells are 
continuously exposed to hyperglycemic conditions for long periods of time. Therefore the 
duration of the hyperglycemic exposure was also addressed and manipulated such that it 
would properly elicit a response seen in diabetic nephropathy. With these conditions in 
mind, the first goal was to determine how well the HPT cells responded to a longer 
exposure period and also if they could tolerate being passaged in hyperglycemic 
conditions. 
Both HPT and RPTEC/TERT1 (ATCC CRL-4031) cells were able to tolerate 
exposures to and passage in the hyperglycemic conditions with no cell death evident of 
the cell viability assay.  However, prolonged exposures to the hyperglycemic conditions 
underwent a morphology change. These cells were more elongated and less cuboidal in 
shape as seen in the earlier passages. When processes like this occur, it’s commonly 
associated with an epithelial to mesenchymal transition that is known to have a role in the 
onset of fibrosis that occurs in the severe disease states of diabetic nephropathy (Carew, 
Wang, & Kantharidis, 2012b; Grabias & Konstantopoulos, 2014). This phenomenon is 
addressed in more detail in the second chapter.   
Although the cell model systems utilized in this study were able to tolerate the 
hyperglycemic conditions, they are missing or have low expression of key glucose 
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transporters. The proximal tubule cell is well- known of its reabsorbing and transporting 
properties however through the culturing process of these cells they lose their brush 
border. Sodium-coupled transporters which is the primary source of glucose re-uptake by 
these cells is located in the brush border which could explain the lack of expression in the 
proximal tubule cell model systems. However the lack of these transporters in proximal 
tubule cell model systems is not addressed in literature.  
Since all proximal tubule cell model systems utilized by this lab lack these 
transporters, to get a better understanding of complications induced by hyperglycemic 
exposures, the primary HPT cells would be better model system to use. The HPT cells 
were more sensitive to the different glucose concentrations in comparison to the lack of 
response by the immortalized RPTEC/TERT1 (ATCC CRL-4031) cell model system. 
Also when investigating human diseases, it is ideal to use human model systems because 
they will elicit the closest pathophysiological response as the seen in the organ.  
To have the best model to use for studying diabetic nephropathy, it would need all 
its physiological properties. As a future direction for this study, the HPT cells should be 
transfected with a sodium- coupled transporter and this study re-investigated.    
Involvement of AKR1B10 in Hyperglycemic Conditions 
As mentioned in the introduction, the polyol pathway has been heavily studied 
since its first discoveries and role in diabetic cataracts (Das & Srivastava, 1985; Shaw et 
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al., 2014; VAN HEYNINGEN, 1959). Findings from these earlier studies eluded to 
sorbitol accumulation being the driving factor for complications associated with diabetes 
cataracts and inhibition of aldose reductase eliminates such complications. These findings 
set the stage for future investigations of complications of diabetic mellitus.  
Previous studies from this lab have investigated the response of HPT cells 
exposed to hyperglycemic conditions through the polyol pathway. Initial studies have 
shown HPT cells exposed to glucose concentration ≥11 mM for 24 hours have a 2-fold 
induction of aldose reductase, AKR1B1, activity and induction of sorbitol accumulation 
that is reduced to normal levels when AKR1B1 is inhibited (Bylander & Sens, 1990)The 
early studies and evidence for the involvement of the polyol pathway in diabetes mellitus 
complications became the new target for the establishment of  pharmaceutical inhibitors 
and treatments for this disease (Dvornik et al., 1973; Hotta et al., 2006; Srivastava, 
Ramana, & Bhatnagar, 2005). The fact that AKR1B1 expression in HPT cells is induced 
within the first 8 days of exposure to hyperglycemic conditions but not the latter passages 
is highly suggestive of the initial involvement of this isoform in contributing to sorbitol 
accumulation. Whereas long-term damage that is associated prolong exposures to 
hyperglycemic conditions is contributed to by this other aldose reductase isoform, 
AKR1B10.  
AKR1B1 and AKR1B10 belong to same aldose reductase family of the polyol 
pathway (Petrash, Flath, Sens, & Bylander, 1992). These enzymes are responsible for 
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metabolizing intracellular toxic carbonyl compounds in physiological conditions however 
in a state of hyperglycemia metabolizes the extra glucose to sorbitol rendering the system 
highly susceptible to damage by reactive oxygen species (Michael Brownlee, 2005; 
Crosas et al., 2003; Huang et al., 2016).  
The results from these studies have demonstrated that prolong exposures to 
hyperglycemia induce the expression of AKR1B10 and knock down of this isoform 
significantly decreases the amount of intracellular accumulated sorbitol. Therefore, 
AKR1B10 has a role in the extra glucose handling associated with diabetes mellitus and 
could also serve as target for drug treatments. The consequences of activation of 
AKR1B10 hasn’t been fully established in diabetic nephropathy however one can 
postulate there would be an increase in cellular damage due to oxidative and osmotic 
stress that contributes to the progression of diabetic nephropathy.   
Exposure to Cadmium Toxicity Induced AKR1B10 Expression 
AKR1B10 is the least understood and studied aldose reductase isoform such that 
there could be other factors that may lead to the activation of this enzyme. Results from a 
global microarray analysis conducted on HPT cells exposed acutely and chronically to 
cadmium showed an induction of AKR1B10 (Garrett et al., 2013, 2011). Results from the 
present study have confirmed the findings from the global microarray data that acute and 
chronic exposures to cadmium toxicity significantly induced AKR1B10 expression more 
so than AKR1B1 expression. Prolong exposures to cadmium toxicity is capable of 
68 
 
inducing several detrimental health effects. This is due to the fact cadmium is a 
nephrotoxicant and has a long-half such that it easily accumulates within the proximal 
tubule cell promoting damage, a hallmark signature of cadmium induced toxicity (Garrett 
et al., 2011; Satarug, Garrett, Sens, & Sens, 2009).  
Although there are little to no studies that can support the findings of activation of 
the polyol pathway by cadmium toxicity, this study can bring forth a new area of research 
for understanding the involvement of environmental toxicants in contributing to the 
disease progression of diabetic nephropathy.  
Cadmium Toxicity has a Role in Progression of Diabetes Mellitus 
Epidemiological studies involving the long-term effects of cadmium exposures in 
the human population have educated the not only researchers and health professionals but 
also the general public about the adverse health effects that could occur if cadmium 
exposure is not limited. Some early studies from Japan recognized a correlation between 
cadmium exposures and increased incidence of kidney diseases and osteomalacia known 
as “itai-itai” diseases (AOSHIMA, 2017; EMMERSON, 1970) 
There have been other epidemiological studies that showed exposures to cadmium 
toxicity increased the risk for diabetes mellitus however if the exposure was limited or 
completely eliminated that risk for the onset of diabetes mellitus was minute 
((Swaddiwudhipong et al., 2012, 2015; Tinkov et al., 2017).  
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In light of the increasing evidence and support for the role of cadmium toxicity 
and the onset or progression of diabetic mellitus this current study also supports this link. 
Results have shown cadmium toxicity induces AKR1B10 expression and the same trend 
is seen in a combined exposure of both cadmium and hyperglycemia. Although the 
effects are not additive, both cadmium and hyperglycemia are inducing damage 
synergistically through the activation of AKR1B10. Therefore it can be postulated that 
AKR1B10 can be a marker for cadmium induced toxicity in relation to the disease 
progression of diabetic nephropathy. 
Role of Oxidative Stress in Diabetic Nephropathy 
Activation of the polyol pathway by hyperglycemic events has been shown to 
cause oxidative and osmotic stress that leads to the onset of complications of diabetic 
nephropathy. When the polyol pathway is activated it promotes to oxidative and osmotic 
stress in three ways; 1) decreased availability of NADPH for usage by glutathione 
reductase which reduces glutathione disulfide to glutathionine protecting against reactive 
oxygen species, 2) increased accumulation of intracellular sorbitol and 3) increased 
production of reactive oxygen species (M Brownlee, 2001; Burg, 1988; Srivastava et al., 
2005; Tang & Lai, 2012). However results from this study also show hyperglycemic 
conditions induce the expression of TXNIP.  
TXNIP contributes to oxidative stress and damage by inihibiting the activity of 
thioredoxin (Singh, 2013). Thioredoxin acts as an antioxidant utilizing NADPH to reduce 
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reactive oxygen species in physiological conditions. However in state of hyperglycemia 
thioredoxin is inhibited in two ways; 1) binding of TXNIP to the catalytic site and 2) 
limited availability of NADPH. Results from the global microarray analysis on HPT cells 
exposed and passaged in glucose for 24 days (P3) showed induction of TXNIP where 
expression levels were confirmed by qPCR and western blot techniques. Since the aldose 
reductase enzymes utilize NADPH for their reducing properties it could be argued that 
activation of the aldose reductase contributes to inhibition of thioredoxin promoting an 
increased accumulation of reactive oxygen species.  
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Chapter V 
Conclusions/ Future Directions 
Diabetic nephropathy is a complicated disease where current treatments aim to 
prevent the disease progression into renal fibrosis but are unable to do so. This study has 
shown the complexities of the disease in primary and immortalized proximal tubule cell 
model systems. Primary and immortalized proximal tubule cell model systems have 
shown to have different biological responses to exposures to hyperglycemia.  
The primary or immortalized cell model system’s response to hyperglycemia has 
some variation as evident in the data of the polyol pathway enzymes. Primary HPT cells 
have shown an induction of aldose reductase enzymes, AKR1B1 and AKR1B10, whereas 
the RPTEC/TERT1 (ATCC CRL-4031) cells have shown a little to no induction of the 
same enzymes. Activation of the aldose reductase enzymes have also led to an 
intracellular sorbitol accumulation in primary HPT cells but not in RPTEC/TERT1 
(ATCC CRL-4031), another major difference between these cell model systems.  
When attempting to understand human diseases it is best to start with the best 
model system and correct exposures of the toxicants being studied. For this project, 
having access to primary kidney cells have set this study apart from those that do not 
have access. This is because the elicited response should be almost similar to what is seen 
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in the whole organ. However it also best to ensure the cells used maintain their 
physiological properties.  
The proximal tubule cells utilized in this study did not express key glucose 
transporters. Therefore, these glucose transporters should be transfected in the kidney 
cells and the study be reinvestigated although the lack of expression of these transporters 
did not have an effect on the glucose utilization by these kidney cells.  
All in all this study sheds some light into possible avenues that could be 
investigated further to determine if the alternative isoform of aldose reductase, AKR1B10 
can also serve as a biomarker for the disease progression of diabetic nephropathy.  
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CHAPTER II 
Abstract 
Renal fibrosis is a major complication associated with the disease progression  of 
diabetic nephropathy (DN) to end-stage renal disease (ESRD), where prolong exposure to 
hyperglycemia induces damage to proximal tubule cells of the kidney. Since progression 
to ESRD correlates to pathological changes in the tubular segments of the kidney, the 
effects of hyperglycemia in the proximal tubule portion of the nephron may be 
particularly relevant to the progression of DN. Epithelial to mesenchymal transition 
(EMT) of proximal tubule cells may play a role in the disease manifestation and 
progression. The goal of this study was to characterize the pathological changes that 
occur in human proximal tubule (HPT) cells exposed to hyperglycemia.  For this purpose, 
cells were exposed to one of the following treatments; 5.5 (control), 7.5, 11, or 16 mM 
glucose concentrations for 8 days then consecutively subcultured for two more passages. 
Real-time PCR and western blot analysis was used to measure the expression levels of 
CDH2 and CDH1 at the mRNA and protein levels, respectively. Exposures to 
hyperglycemia induced morphological changes and stimulated a significant induction of 
CDH2 in HPT cells; however, exposure had no effect on CDH1 expression. 
Hyperglycemia also induced the expression of SNAI1 at the mRNA level. The data from 
the current study suggests hyperglycemic induced damage of the proximal tubule in the 
kidney during the development of DN occurs through an EMT phenomenon. 
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Introduction 
  There are several complications associated with diabetic nephropathy. One 
process that seems to be the most daunting is the onset of fibrosis. Renal fibrosis is an 
inevitable consequence that is seen in progressive chronic kidney diseases which occurs 
when the kidney is no longer able to regenerate to heal itself. Evidence of fibrosis (or 
scarring) leads to the loss of renal function eventually progressing into end-stage renal 
disease. At this point, the only form of treatment is to have the patient undergo renal 
dialysis or transplantation which is a major cost burden (Zeisberg & Kalluri, 2004)   
 Renal fibrosis is characterized as an excessive deposition of extracellular matrix 
(ECM) in the tubulointerstitium, glomerulus, and vasculature (Zhou & Liu, n.d.).  
Although the mechanism behind the irreversible damage is least understood, a common 
denominator exists regardless of the primary cause which is the activation of 
myofibroblasts.  Activation of myofibroblasts occurs when the wound healing process is 
initially turned on in response to mediators such as cytokines or growth factors produced 
by injured resident epithelial cells (Efstratiadis, Divani, Katsioulis, & Vergoulas, 2009) 
however fibrosis occurs when this process is continuous for long periods of time.  
 Early studies regarding renal fibrosis has been extensively focused on glomerular 
cells (Danne, Spiro, & Spiro, 1993; D. Wang et al., 2015) because it was believed 
damage to this region of the kidney would be the driving force for other complications 
associated with diabetic nephropathy. However within the past decade of kidney fibrosis 
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investigations, researchers have begun to appreciate tubulointerstitium damage also 
contributes to the severity of the disease but also serve as a predictor of progression. 
 There are various cellular components contributing to the onset of renal fibrosis. 
All cell types within the kidney are known to participate in the pathogenesis of renal 
fibrosis however it is widely accepted the fibroblasts/myofibroblasts are the main cell 
type responsible for accumulation of interstitial extra-cellular matrix (Carew, Wang, & 
Kantharidis, 2012a; Efstratiadis et al., 2009; A.M. El Nahas, Muchaneta-Kubara, 
Essaway, & Soylemezoglu, 1997). Activated fibroblasts are recognized by their 
production of α smooth muscle actin (αSMA) (Hewitson, 2012; Zhou & Liu, n.d.), 
however the source behind fibroblast activation or the origin of these cells is least 
understood.  
 After several theories and speculations, a study characterizing the differences 
between fibroblasts and epithelium found one gene is active in the promoter region of 
fibroblasts but not epithelium. This gene came to be known as fibroblast specific protein 
1 (FSP1) and is observed in injured regions of the tubular sections of the kidney 
undergoing fibrosis, indicating tubular epithelial cells were converting to fibroblast in 
response to injury (Strutz et al., 1995). This process of resident epithelial cells converting 
into cells with characteristics of fibroblasts is known as epithelial to mesenchymal 
transition (EMT).  
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 There are three types of epithelial to mesenchymal transition processes. Type 1 
epithelial to mesenchymal transition occurs during organogenesis where immature 
mesenchymal cells give rise to the mature epithelium. Type 2 epithelial to mesenchymal 
transition occurs during the tissue repair process such as fibrosis, resulting in 
myofibroblasts formation from resident epithelium to heal the injured regions of the 
tissue. Type 3 epithelial to mesenchymal transition results in malignant cells having the 
ability to metastasize and invade nearby tissue (Figure 2.1.1) (Tennakoon, Izawa, 
Kuwamura, & Yamate, 2015). 
Figure 2.1. Types of epithelial to mesenchymal transition processes. Adapted from 
Zeisberg and Neilson, 2009.  
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 Tubular epithelial to mesenchymal transition is defined as the process where 
resident renal epithelial cells lose their epithelial characteristics and obtain features of 
mesenchyme (Zhou & Liu, n.d.). Epithelial cells are derived from the metanephric 
mesenchyme in the reverse process of epithelial to mesenchymal transition, mesenchymal 
to epithelial transition (MET) (Hay & Zuk, 1995). During homeostasis, renal epithelial 
cells have distinct features that allow them to maintain the tissue’s organization. For 
instance, renal epithelium has apical and basolateral surfaces that are easily 
distinguishable from each other. The apical membrane is lined with a brush border that 
helps to facilitate the maximal reabsorption of nutrients. The polarity of the epithelium is 
regulated by adherens junctions and tight junctions.  
 Adherens junctions are composed primarily of E-cadherin (CDH1) and maintain 
cell integrity by interacting with other E-cadherin proteins on neighboring cells 
(Gumbiner, 2005; Yonemura, Itoh, Nagafuchi, & Tsukita, 1995). Tight junctions have 
two primary proteins, occludins and claudins with each having separate roles in 
maintaining the tight junction between cells (Hartsock & Nelson, 2008). All these 
proteins have a profound role in maintaining organization of the cell but when there is 
damage to these proteins, the epithelial cell organization is compromised.  
 The hallmark of epithelial to mesenchymal transition is the loss of E-cadherin 
from the adherens junctions resulting in a dramatic remodeling of the cytoskeleton 
resulting in a loss of adhesion and polarity and an increase in N-cadherin (CDH2) 
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expression, a phenomenon called the cadherin switch (Tennakoon et al., 2015). Along 
with the induction of cytoskeletal markers such as α-SMA, vimentin, fibroblast specific 
protein -1 and β-catenin, these markers have been studied in context of Type 2 epithelial 
to mesenchymal transition occurring in injured renal epithelial cells (Zeisberg & Neilson, 
2009).  
Hypothesis/ Rationale 
Primary and immortalized proximal tubule cells continuously exposed and 
passaged in hyperglycemia experienced a morphology change from a more cuboidal to an 
elongated shape. Because this characteristic is evident of an EMT process, it would be 
suggested EMT markers such as N/E-Cadherin, vimentin, fibronectin to name a few will 
be induced in HPT cells in response to exposure and passaging in hyperglycemic 
conditions.  
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CHAPTER II.II 
Methods 
RNA isolation and RT-qPCR 
Total RNA was purified from cultures of HPT or RPTEC/TERT1 (ATCC CRL-
4031) cells utilizing TRI Reagent (Molecular Research Center, Inc.) and quantified by 
spectrophotometry (Nanodrop).  100 ng of total RNA was subjected to cDNA synthesis 
using the iScript cDNA synthesis kit (Bio-Rad) for a final volume of 20 μL. Gene 
expression was measured with real-time reverse transcription polymerase chain reaction 
(RT-PCR) using primers of interest (see Table 1.2.1). Real time PCR was performed 
using SYBR Green (Bio-Rad) with 2 μL cDNA and .2 μM primers in a final volume of 
20 μL in the CFX96 Touch Real-Time detection system (Bio-Rad). SYBR Green 
fluorescence was used to monitor the amplification of the reaction and further analyzed 
by interpolation from a standard curve.  
 
Gene Company Catalog No.  
ACTA2 BioRad qHsaCID0013300 
CDH1 BioRad qHsaCED0042076 
CDH2 BioRad qHsaCID0015189 
OCLN BioRad qHsaCED0038290 
Snail1 BioRad qHsaCED0038290 
TGFB1 BIORAD qHsaCID0017026 
Twist BioRad qHsaCED0043959 
Vimentin BioRad qHsaCID0012604 
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Table 2.2.1 Primer Information 
 
Protein Isolation  
For the glucose studies, total protein was isolated from HPT cells using a 2% 
Sodium Dodecyl Sulfate (SDS) lysis buffer containing 50 mM Tris-HCL, pH 6.8 with 
1% protease inhibitor cocktail (Sigma-Aldrich). Cell pellets were homogenized in the 
lysis buffer, boiled for 10 minutes and subjected to DNA shearing by sonication. Protein 
concentration was determined by BCA assay (Pierce). Samples were stored at -80ºC in 
100 mM dithiothreitol.  
For the cadmium and glucose studies with RPTEC/TERT1 (ATCC CRL-4031) 
cells, total protein was isolated from the HPT and RPTEC/TERT1 (ATCC CRL-4031) 
cells using a RIPA lysis buffer containing protease inhibitors, PMSF, and sodium 
orthovandate (Santa Cruz). Cell pellets were homogenized in cold RIPA lysis buffer at a 
1:2 w/v ratio and incubated on ice, with orbital shaking for 30 minutes. The samples were 
then sonicated and centrifuged at 10,000g for 10 minutes at 4°C. The supernatant was 
collected in cold, separate tubes and subjected to BCA assay (Pierce) for protein 
quantification and stored -80ºC.  
Western Blot Analysis 
 Protein expression was measured by western blot techniques. Twenty µg protein 
was separated by SDS-Page using the TGX AnyKd SDS polyacrylamide gel (Bio-Rad). 
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Samples contained equal amounts of protein and Laemmli buffer (Bio-Rad) containing β-
mercaptoethanol. The samples were then boiled for 5 minutes at 95ºC to reduce protein. 
Once samples were back to room temperature, they were loaded into the gel. Proteins 
were then transferred to a .2 µm PVDF membrane using a Trans-blot Turbo transfer 
apparatus (Bio-Rad). After transfer, the membranes were blocked with 5% nonfat dry 
milk in TBS-T for 90 minutes. Blots were incubated in 4ºC in the primary antibodies 
overnight on an orbital shaker. Table 1.2.1 has a list of all antibodies. 
Antibody Name Mw (kDa) Dilution Species Company Catalog No. 
ACTA2 42 1:1000 Rabbit Abcam Ab5694 
ACTB 42 1:3000 Mouse Abcam Ab8226 
CDH1 120  Rabbit Santa-Cruz Sc-7870 
CDH2 137 1:1000 Mouse Invitrogen 333900 
Table 2.2.2 Antibody source.  
Transepithelial Resistance 
Transepithelial resistance was measured in HPT or RPTEC/TERT1 (ATCC CRL-
4031) cells exposed to hyperglycemia. HPT or RPTEC/TERT1 (ATCC CRL-4031) cells 
were seeded at a 2:1 ratio in triplicate onto a 24 mm-diameter cellulose ester membrane 
inserts (Corning). The inserts were then placed into six-well plates. On the third day post-
seed, HPT or RPTEC/TERT1 (ATCC CRL-4031) cells started 5.5, 7.5, 11, 16 mM 
glucose treatments. On the first day of the glucose treatments, transepithelial resistance 
(TER) was measured every day for twelve days with the EVOM Epithelial Voltohmmeter 
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(World Precision Instruments, Sarasota, FL) with a STX2 electrode according to 
manufacturer’s instructions. The resistance of a filter containing control medium but with 
no cells was subtracted from filters containing a monolayer of cells. The corrected 
resistance values were multiplied by the surface area of the filter (available for growth) to 
get a final unit of area resistance. Three sets of four readings were taken at four different 
quadrants on each filter. The morphology of the monolayer was monitored for dome 
formation in a separate 6-well plate without inserts. The experiment was repeated twice 
and the final replicate recordings were reported as the ±SEM.  
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CHAPTER II.III 
Results 
HPT Cells Passaged in Glucose Exhibit a Morphology Change 
HPT cells continuously exposed and passaged in glucose for 24 days (P3) had 
showed signs of morphology change. These changes were captured using a light/dark 
phase contrast microscope. In the first 8 days (P1) of exposure, the HPT cells are still 
forming domes (outlined regions) and are cuboidal in shape (Figure 2.3.1). However, as 
these cells are continuously exposed and passaged in hyperglycemic conditions, they 
undergo a morphology change. These cells become more elongated (Figure 2.3.2) and not 
as cuboidal in shape as seen in the first passage (Figure 2.3.1).  
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Figure 2.3.1 Light Level Morphology of HPT cells Exposed to Glucose for 8-Days. 
Human proximal tubule cells exposed to 5.5 mM (control), 7.5 mM, 11 mM, and 16 mM 
glucose for 8 days. Highlighted boxed represent regions of dome formation.   
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Figure 2.3.2 Light level morphology of HPT cells exposed and passaged in Glucose 
for 24-days.  Human proximal tubule cells exposed and passaged in 5.5 mM (control), 
7.5 mM, 11 mM, or 16 mM glucose for 24 days (P3). Black arrows represent regions of 
irregular morphology.  
 
CDH2 Expression is Induced in HPT Cell Passaged in Glucose 
Evidence from the morphology changes in response to being exposed and 
passaged in high concentrations of glucose is suggestive of an EMT process. This process 
is characterized by the E-Cadherin (CDH1) and N-Cadherin (CDH2) switch however 
there are other markers that when induced could indicate an EMT process occurring. 
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These other markers are: fibronectin (FN1), vimentin (VIM), smooth-muscle actin 
(ACTA2) and transcription factors: snail (SNAI1), slug (SNAI2), twist (1/2). Measured the 
expression of CDH1 and CDH2 in HPT cells exposed and passaged in glucose.  
 The expression of CDH1 is induced in the first 8 days of exposure by 16 
mM glucose but then no induction in 16 day  (P2) exposure and is  back to being induced 
in 24 days (P3)  exposure by 16 mM (Figure 2.3.3 A). On the other hand, CDH2 
expression in continuously induced by 16 mM glucose exposure across all three passages, 
with a 6 to 7-fold induction in the 24 day (P3) exposure (Figure 2.3.3 B). The induced 
expression is translated into the protein analysis as well.  
ACTA2 expression levels were shown to be affected by the hyperglycemic 
conditions. In the first 8 days (P1) of exposure, there is a 2-fold induction of ACTA2 by 
16 mM glucose to a 10 to 15- fold induction by 16 days of exposure (P2). After 24 days 
(P3) of being in hyperglycemic conditions, there is steady and significant induction of 
ACTA2 (Figure 2.3.4).  However both VIM and FN1 expression were not induced in 
HPT cells exposed and passaged in 5.5, 7.5, 11, 16 mM glucose (Figure 2.3.5 A, B).  
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Figure 2.3.3 CDH1 and CDH2 expression in HPT cells exposed and passaged in 
glucose.  RT-PCR and protein analysis of CDH1 (A) and CDH2 (B) in HPT cells 
exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change 
normalized to ACTB. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, 
***p<0.001 
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Figure 2.3.4 ACTA2 mRNA expression in HPT cells exposed and passaged in 
glucose.  RT-PCR and protein analysis of ACTA2 in HPT cells exposed and passaged in 
5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change normalized to ACTB. RT-
PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001Junctions 
Proteins are not Affected by Glucose Toxicity 
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Figure 2.3.5 VIM and FN1 mRNA expression in HPT cells exposed and passaged in 
glucose.  RT-PCR and protein analysis of VIM (A) and FN1 (B) in HPT cells exposed 
and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change normalized 
to control. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.00 
 
All of aforementioned genes are turned on by certain transcription factors. SNAI1 
and TWIST1 are common transcription factors that will induced an EMT response. 
Expressions of both SNAI1 and TWIST1 were measured in HPT cells exposed and 
passaged in glucose. SNAI1 expression is induced ~3-fold in the first 8 day (P1) 
exposure to 16 mM glucose (Figure 2.3.6 A). On the other hand, TWIST1 expression is 
induced 10 - 20–fold in HPT cells exposed to hyperglycemic condition for 16 days (P2) 
or longer (P3) (mRNA data only) (Figure 2.3.6 B). There is no western analysis for 
TWIST1 protein expression due to antibody problems.  
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Figure 2.3.6 SNAI1 and TWIST expression in HPT cells exposed and passaged in 
glucose.  RT-PCR and protein analysis of SNAI1 (A) and TWIST (B) in HPT cells 
exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change 
normalized to ACTB. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, 
***p<0.001  
Junctional Proteins are not Affected by Exposures to Hyperglycemia 
Claudin and occludin proteins are found at the intercellular junctional complexes. 
These proteins help to establish tight junctions and maintain the stability and barrier 
properties of tight junctions.  Since passaging of HPT cells in high levels of glucose 
causes morphology changes, it would be possible that glucose could affect the expression 
of these tight junction proteins. However data from this study has shown HPT cells 
exposed and passaged in glucose had no effect on the following tight junction proteins; 
claudins-1/2, (Figure 2.3.7 A, B) and occludin-1 (Figure 2.3.8).  
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Figure 2.3.7 CLDN1 and CLDN2 mRNA expression in HPT cells exposed and 
passaged in glucose.  RT-PCR and protein analysis of CLDN1 (A) and CLDN2 (B) in 
HPT cells exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold 
change normalized to control. RT-PCR results represent ±SEM of triplicate. *p<0.05, 
**p<0.01, ***p<0.001 
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Figure 2.3.8 OCLN1 mRNA expression in HPT cells exposed and passaged in 
glucose.  RT-PCR and protein analysis of OCLN1 in HPT cells exposed and passaged in 
5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change normalized to control. RT-
PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, ***p<0.001 
 
Gap junction proteins, GJB1 and GJB2, expression was also measured to 
determine if hyperglycemia had altered their expression.  Within the first passage in 
glucose, both GJB1 and GJB2 expression was induced in response to increasing glucose 
concentrations (Figure 2.3.9 A,B). GJB1 expression was also induced in HPT cells 
exposed and passaged in glucose for 24 days (P3) however (Figure 2.3.9 A), GJB2 was 
not induced in the latter passages (Figure 2.3.9 B).  
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 Figure 2.3.9 GJB1 and GJB2 mRNA expression in HPT cells exposed and passaged 
in glucose.  RT-PCR and protein analysis of GJB1 (A) and GJB2 (B) in HPT cells 
exposed and passaged in 5.5, 7.5, 11, 16 mM glucose. Data expressed as a fold change 
normalized to control. RT-PCR results represent ±SEM of triplicate. *p<0.05, **p<0.01, 
***p<0.001 
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CHAPTER II.IV 
Discussion 
The present study establishes that HPT cells in a prolonged hyperglycemic 
environment undergo a partial EMT process. Chronic kidney disease is a global epidemic 
and becoming a worldwide healthcare burden not only to the health care physicians but 
more importantly to the patient. Progressive injury to the kidneys results in renal fibrosis 
which is the final pathway for all chronic kidney diseases and the point at which 
irreversible damage is prevalent. At this state, there are no therapeutic treatments other 
than kidney transplantation or life-long dialysis treatments therefore understanding the 
mechanisms behind the development of renal fibrosis will help to develop therapeutic 
targets for inhibiting the disease progression of diabetic nephropathy into renal fibrotic 
state.  
 The present study provides an insight into a potential mechanism of the gradual 
damaging process that may occur during the disease transition of diabetic nephropathy to 
a fibrotic state. Several studies have suggested dedifferentiation of renal epithelial cells 
through type 2- EMT process has a role in the onset of fibrosis. EMT is a biological 
process that has a major role in developmental and pathological properties such as the 
loss of apical-basolateral polarity, loss of cell to cell contact, and reorganization of 
cytoskeletal actin (Expósito-Villén, E. Aránega, & Franco, 2018; Kizu, Medici, & 
Kalluri, 2009).   These genetic alterations promotes the transition of epithelial cells into 
cells with mesenchymal features which is commonly characterized by an induction of N-
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cadherin and a repression of E-cadherin (Iwano et al., 2002; Lovisa et al., 2015; Zeisberg 
& Kalluri, 2013; Zeisberg & Neilson, 2009). 
 Results from this study suggest there is an EMT process occurring through the 
activation of CDH2, SNAI1, ACTA2, TWIST genes in response to exposures to 
hyperglycemica. Although there were several epithelial markers that had no change in 
expression such as CDH1, Claudin-1/2, occludin, GJB-1/2, these cells may have been 
caught in the early stages of initiating a mesenchymal state. This partial transition is also 
depicted in the morphology images HPT cells exposed and passaged in hyperglycemia 
where some cells appear to be “elongated” in shape whereas others are more “cuboidal”.   
There is a lack of support in the literature for the evidence of the EMT 
phenomenon occurring in only some of the cells because researchers in this area of the 
field believe the EMT process is an all-or-none phenomenon. In a study conducted by 
Grande et al., 2015, had shown activation of SNAI1 in mouse renal epithelial cells 
promotes signals for myofibroblast differentiation without inducing the myofibroblast 
population (Grande et al., 2015) supporting the idea of a “partial” EMT process. In 
another study where immortalized proximal tubule cells were exposed to 25 mM glucose 
for 48 hours, showed appreciable high expression of vimentin and α-smooth muscle actin 
and repressed expression of e-cadherin (Liu et al., 2016). 
Although there have been several studies investigating EMT processes and its role 
in renal fibrosis, there are still remains several controversies regarding if EMT is the 
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driving force for the development of fibroblasts. However, as researchers continue to 
investigate the relationship between EMT and renal fibrosis, there will be a possible 
therapeutic approach to prevent renal fibrosis.  
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